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The past two decades have witnessed many advances in the prevention, treatment, and 
control of diabetes mellitus (DM) and its complications. Increased screening has led to 
a greater recognition of type 2 diabetes mellitus (type 2 DM) and prediabetes; however, 
Hispanics/Latinos, the largest minority group in the US, have not fully benefited from 
these advances. The Hispanic/Latino population is highly diverse in ancestries, birth 
places, cultures, languages, and socioeconomic backgrounds, and it populates most of 
the Western Hemisphere. In the US, the prevalence of DM varies among Hispanic/Latino 
heritage groups, being higher among Mexicans, Puerto Ricans, and Dominicans, and 
lower among South Americans. The risk and prevalence of diabetes among Hispanics/
Latinos are significantly higher than in non-Hispanic Whites, and nearly 40% of Hispanics/
Latinos with diabetes have not been formally diagnosed. Despite these striking facts, 
the representation of Hispanics/Latinos in pharmacological and non-pharmacological 
clinical trials has been suboptimal, while the prevalence of diabetes in these populations 
continues to rise. This review will focus on the epidemiology, etiology and prevention 
of type 2 DM in populations of Latin American origin. We will set the stage by defining 
the terms Hispanic, Latino, and Latin American, explaining the challenges identifying 
Hispanics/Latinos in the scientific literature and databases, describing the epidemiology 
of diabetes—including type 2 DM and gestational diabetes mellitus (GDM)—and cardio-
vascular risk factors in Hispanics/Latinos in the US and Latin America, and discussing 
trends, and commonalities and differences across studies and populations, including 
methodology to ascertain diabetes. We will discuss studies on mechanisms of disease, 
and research on prevention of type 2 DM in Hispanics/Latinos, including women with 
GDM, youth and adults; and finalize with a discussion on lessons learned and opportu-
nities to enhance research, and, consequently, clinical care oriented toward preventing 
type 2 DM in Hispanics/Latinos in the US and Latin America.
Keywords: type 2 diabetes mellitus, gestational diabetes, prevention of diabetes, Latinos, Latin America, 
epidemiology of type 2 diabetes, Hispanics
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iNTRODUCTiON
Poverty is the best cure for diabetes.
La pobreza es el mejor remedio contra la diabetes.
-Gabriel García Márquez (1)
Diabetes mellitus (DM) has been documented in the medical 
history of some Latin American countries since the late 1800s and 
early 1900s (2, 3). Although not a common disease at that time, 
type 1 DM was highlighted by medical societies in the Americas 
due to its dramatic presentation and fast clinical deterioration. 
In contrast, type 2 diabetes mellitus (type 2 DM) and its long-
term complications only gained attention in the mid-twentieth 
century (2, 3). Over the next decades, type 2 DM would become 
recognized not just as a common chronic disease but also as one 
of the leading causes of death worldwide (4).
why is it important to Understand Type 2 
Diabetes in Hispanics/Latinos in the US 
and in Latin Americans?
Hispanics/Latinos in the US mainland constitute 17.6% of the 
population (5), and are the largest US minority group. It is 
projected that by year 2060, 29% of the US population will be of 
Hispanic/Latino descent (6). Compared to other US populations, 
the Hispanic/Latino population is younger, with nearly half of 
the US-born Hispanics/Latinos under age 18 (7). The prevalence 
of diabetes among Hispanics/Latinos in the US is 22.6%, and 
twice as high as that of non-Hispanic Whites (NHWs) (11.3%) 
(8). Diabetes has also become a leading cause of death in Latin 
America (9, 10).
Understanding type 2 DM among Hispanics/Latinos in the US 
and in Latin America poses several challenges. A long-standing 
assumption in the US is that Hispanics/Latinos are a demographi-
cally and ancestrally homogeneous group. However, as we will 
explain, Hispanics/Latinos are a highly heterogeneous group, and 
in fact, the prevalence of diabetes varies widely among different 
US Hispanic/Latino heritage groups (11–13). These differences 
in prevalence may be mediated by differences in ancestry, as well 
as differences in socioeconomic factors, cultural norms, dietary 
and physical activity (PA) patterns, and history of environmental 
exposures—among others—experienced in both the country of 
origin and the US.
As the foundations for precision and personalized medicine 
are built, it is clear that adequate prevention, diagnosis, and 
treatment of type 2 DM among Hispanics/Latinos in the US 
and in Latin America require deep understanding of its etiology, 
manifestations, and response to interventions across populations. 
Whereas diabetes has become a seemingly unavoidable outcome 
for many Hispanics/Latinos, it does not have to be so.
In this expert review, we will describe the epidemiology of type 
2 DM and gestational diabetes mellitus (GDM) and traditional 
cardiovascular (CV) risk factors in Hispanics/Latinos in the US 
and Latin America based on selected studies. We will also discuss 
studies on the etiology of type 2 DM and GDM in Hispanic/Latino 
populations. Given the increasing prevalence of type 2 DM across 
the continent, and especially at younger ages, we considered 
imperative to focus on research dedicated to disease prevention 
in Hispanics/Latinos in the US and in Latin America. We will 
also highlight opportunities to enhance our knowledge through 
research within a holistic framework of multidimensional and 
transdisciplinary strategies; a framework that is also applicable to 
the clinical care of Hispanics/Latinos at risk of type 2 DM.
In this review, the term type 2 DM will be used throughout 
most of the text, and specially within the context of etiology and 
prevention. The term diabetes will be used within the context of 
epidemiology or when there is no distinction between type 1 and 
type 2 DM. As a reference, we have also included a list of acro-
nyms and abbreviations used throughout the text (see Appendix).
who Are the Hispanics/Latinos in the  
US and Latin Americans?
The Office of Management and Budget (OMB) and the US Census 
Bureau define Hispanic or Latino as “a person of Cuban, Mexican, 
Puerto Rican, South or Central American, or other Spanish 
culture regardless of race” (14). The racial and ethnic categories 
defined by the OMB have been challenged and are under revision 
(15). Figure 1 (16) illustrates where the largest Hispanic/Latino 
heritage groups live in the US and Puerto Rico based on the 2010 
US Census.
The terms Hispanic and Latino have different meanings 
in the US and abroad. Place of residence (17), ancestry group 
(18), or immigrant generation (18) may influence individuals’ 
preference for the term Hispanic, Latino, both, or neither. In 
this review, the term Hispanic/Latino refers to persons of Latin 
American descent who live in the US or in Latin America; that 
is, those who self-identify or trace their roots to countries in 
the Americas where Spanish, Portuguese, and French are the 
predominant languages (19, 20), excluding persons from Spain. 
The term Latin Americans refers to persons or populations in 
Latin America (19, 20).
Sociodemographic and economic 
Characteristics of the Hispanic/Latino 
Population in the US and in Latin America
According to the US Census Bureau, Hispanics/Latinos have 
become the US largest minority group. This population increased 
nearly fourfold between 1980 and 2015, rising from 14.8 million 
(6.5%) to 56.6 million (17.6%) (21–23). The Hispanic/Latino 
population is projected to increase to 119 million, or nearly 29% of 
the population in 2060 (6), with growth attributed to high rates of 
immigration and fertility, and low overall mortality (24). In 2015, 
Hispanics/Latinos of Mexican origin were the largest Hispanic/
Latino heritage group (63%), followed by Puerto Ricans (10%), 
Salvadorans (4%), Cubans (4%), and Dominicans (3%) (21).
As a group, Hispanics/Latinos are younger than other racial/
ethnic groups in the US (median 28.7  years) and lag behind 
other groups in educational attainment (21) (Table 1). At 67%, 
the percentage of Hispanics/Latinos age 25 or older with a high 
school education or higher is significantly lower than that of 
NHWs (91.8%) (25). Poverty rates are significantly higher among 
Hispanics/Latinos (21.4%) than NHWs (9.1%) (26). In the US, 
unemployment among the population aged 16 years and older 
FiGURe 1 | 2010 US Census Map—Largest Detailed Hispanic Origin Group by State: 2010. This is Figure 4 from Ennis et al. (16).
TABLe 1 | Selected socioeconomic indicators for Hispanics/Latinos in the US by heritage group, 2015.a
Race/ethnic group Median age 
(years)
Percent of population 
≥25 years who are 
high school graduate 
or higher
Percent of 
population 
≥16 years who is 
unemployed
Percent of people whose 
income in the past 
12 months is below the 
poverty level
Median family 
income
Percent of civilian 
noninstitutionalized 
population with no health 
insurance coverage
US Mainland
Hispanic/Latino 28.7 66.0 4.9 22.6 $46,690 19.5
Mexican 26.9 60.9 4.9 23.5 $45,616 21.5
Puerto Rican 29.5 78.9 5.9 24.6 $45,693 8.5
Cuban 40.8 79.2 3.9 17.6 $51,105 13.9
Dominican 30.1 68.1 6.4 26.7 $39,762 12.3
Central American 30.1 56.0 4.6 22.2 $43,570 28.2
South American 35.6 85.2 4.3 14.4 $60,169 17.0
Other 31.7 70.8 4.7 20.0 $49,812 19.5
Non-Hispanic White 43.3 92.3 5.0 10.4 $77,072 6.3
Non-Hispanic Black 33.7 84.7 11.3 25.4 $45,014 11.0
Puerto Rico 40.0 74.7 8.4 46.1 $22,428 5.7
aSource: US Census Bureau, 2015 American Community Survey 1-Year Estimates.
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TABLe 2 | Selected socioeconomic indicators for Hispanics/Latinos in Latin America, 2014–2015.
Country Median age  
(years), 2015a
Gross enrollment rate in secondary and 
tertiary education, 2014b
economic participation rate in 
population aged ≥ 15, 2015b
Percentage of population 
classified as poor, 2014b
Argentina 30.8 88.2/NA 59.6 4.3
Bolivia 24.1 75.7/NA 69.6 32.7
Brazil 31.3 NA 66.6 16.5
Chile 34.4 88.3/88.6 57.4 7.8
Colombia 30.0 78.6/51.3 69.4 28.6
Costa Rica 31.4 78.1/53.0 59.6 18.6
Cuba 41.2 NA/41.0 NA NA
Dominican Republic 26.1 65.5/47.5 58.8 37.2
Ecuador 26.6 NA 64.4 29.8
El Salvador 26.7 70.2/28.9 61.6 41.6
Guatemala 21.2 46.7/NA 62.2 67.7
Honduras 23.4 49.3/21.2 61.6 74.3
México 27.4 NA/29.9 63.2 41.2
Nicaragua 25.2 NA 62.4 58.3
Panama 28.7 NA 64.0 21.4
Paraguay 24.9 NA 68.6 42.3
Perú 27.5 78.4/NA 71.8 22.7
Uruguay 34.9 NA 65.8 4.4
Venezuela 27.4 74.8/NA 64.8 32.1
aSource: United Nations, Department of Economic and Social Affairs, Population Division (2015). World Population Prospects: The 2015 Revision, Key Findings and Advance Tables. 
Working Paper No. ESA/P/WP.241.
bSource: Economic Commission for Latin America and the Caribbean (ECLAC), Statistical Yearbook for Latin America and the Caribbean, 2016 (LC/PUB.2017/2-P), Santiago, 2016. 
Data correspond to the most recent available year.
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was highest among non-Hispanic Blacks (11.3%) and islander 
Puerto Ricans (8.4%), and lowest among NHWs (5%) and 
Hispanics/Latinos (4.9%). Islander Puerto Ricans continue to 
have higher poverty rates (46.1%) than other Hispanics/Latino 
groups in the US (22.6%), non-Hispanic Blacks (25.4%), and 
NHWs (10.4%) (21).
Hispanics/Latinos of any race are disproportionately affected 
by lack of health insurance compared to all other groups (27). 
While only approximately 10% of NHWs did not have healthcare 
insurance, nearly 20% of Hispanics/Latinos of any race lack health 
insurance. Within Hispanic/Latino subgroups, the percentage of 
uninsured individuals varied considerably, from 8.5% in Puerto 
Ricans to 28.2% in Central Americans (28, 29).
The population in Latin America and the Caribbean is pro-
jected to grow from 646 million currently to 784 million in 2050 
(30). This population is relatively young with a median age of 
29.2 years (31) (Table 2). Enrollment in secondary and tertiary 
education remains unequal in the region, ranging from 21.2% in 
Honduras to 88.6% in Chile. The percentage of the population 
classified as poor is highly variable, from 4.3% in Argentina to 
over 60% in Guatemala and Honduras.
Challenges in identifying Hispanics/
Latinos in US Government Reports  
and the Scientific Literature
Demographic Terminology
From the late 1800s and through most of the twentieth century, 
several terms have been used in the Census data and the medical 
literature to attempt to identify persons of Mexican origin, and 
later other Hispanics/Latinos (32, 33). Not surprisingly, the terms 
failed to accurately identify this elusive and complex mosaic of 
populations.
Through several modifications to the US Census since 1970 
(33), blanket demographic terms such as “Hispanic” and “Latino” 
have been used to attempt to capture the specific cultural identi-
ties within the “Hispanic or Latino” populations. Despite the 
population’s diversity in virtually every element, this conglomer-
ate of races, nationalities, and cultures is still regarded by many 
as a monolith.
Publications on US Hispanic/Latino Health
The earliest scientific reports on the health of any US Hispanic/
Latino heritage group date from 1929 or earlier (34), and focused 
on tuberculosis in Mexican immigrants. Subsequent studies 
published from the 1950s to the 1970s addressed farm laborers’ 
health (35), folk medicine (36), sociological, psychiatric, and 
behavioral issues (37–42), hematologic and gastrointestinal 
disorders (43–46), infectious and tropical diseases (47–49), 
and women’s fertility (50), among other topics, and focused on 
Mexican immigrants, Puerto Rican migrants, and Puerto Rico. 
Thus, for most of the twentieth century, health-related studies 
in Hispanics/Latinos were isolated and did not address chronic 
diseases; furthermore, the manner in which Hispanics/Latinos 
were classified was inconsistent. Although the Framingham 
Heart Study was initiated in 1948 (51), and its first analyses on the 
incidence of cardiovascular disease (CVD) and associated risk 
factors were published between 1957 and 1959 (52, 53), the study 
of chronic diseases, in particular CV morbidity and mortality, in 
Hispanics/Latinos in the US did not start until the 1960s (54).
As we will describe, differences and similarities in the preva-
lence of diabetes and CV risk factors between Hispanics/Latinos 
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and other racial/ethnic groups, and among Hispanic/Latino her-
itage groups would gradually be documented by various studies 
across the US. Understanding these differences and similarities 
could shed light on the interaction among various health deter-
minants, and diabetes risk across populations. These differences 
and similarities are still being investigated.
ePiDeMiOLOGY OF DM iN HiSPANiCS/
LATiNOS iN THe US AND LATiN AMeRiCA
Diabetes in Hispanics/Latinos in the US
During the past three decades of the twentieth century, 
reports about chronic diseases—including diabetes—in the 
US Hispanic/Latino population started to be generated and 
disseminated through several epidemiological studies, includ-
ing but not limited to the Puerto Rico Heart Health Program 
(54, 55), the Laredo Project (56), the San Antonio Heart 
Study (SAHS) (57, 58), the Hispanic Health and Nutrition 
Examination Survey (Hispanic HANES) (11, 59, 60), the San 
Luis Valley Diabetes Study (61), and later the National Health 
Interview Survey (NHIS) (28), the Behavioral Risk Factor 
Surveillance Survey (BRFSS) (62), and the National Health 
and Nutrition Examination Survey (NHANES) (63). However, 
most of the studies were cross-sectional and focused on one 
Hispanic/Latino heritage group or specific region of the US. 
Of these, the Hispanic HANES, conducted from 1982 to 1984, 
was the first epidemiological study to describe the prevalence of 
some chronic diseases, including diabetes, in the three largest 
Hispanic/Latino heritage groups at the time: Mexicans, Puerto 
Ricans, and Cubans (11, 59, 60). However, the Hispanic HANES 
was a one-time cross-sectional study. In 2006, the Hispanic 
Community Health Study/Study of Latinos (HCHS/SOL), a 
prospective study, was established to describe the prevalence of 
chronic diseases (especially CV and pulmonary), identify their 
risk or protective factors, and correlate them with future health 
outcomes in a cohort of US Hispanics/Latinos from diverse 
origins in a cohort of over 16,000 Hispanic/Latino adults from 
Central American, Cuban, Dominican, Mexican, Puerto Rican, 
and South American heritage living in San Diego, Chicago, 
Miami, and New York (64, 65).
There are important differences in these studies that make 
comparisons across them difficult: methodological variations 
in selection of study populations, diagnostic criteria to deter-
mine diabetes, lack of assessment to distinguish between type 
1 and type 2 DM, proposed diagnostic cut points (66–68), and 
time-period of analysis. Further caution must be taken when 
interpreting data gathered across studies, because the lack of 
confirmatory testing of diagnostic criteria in some studies could 
result in an inaccurate estimate of the prevalence (66). Since 
some surveys restrict their sampling to specific geographic areas, 
generalizability of the findings to all Hispanics/Latinos living in 
the US or Latin America is reduced.
Table 3 lists selected US epidemiological studies focused on 
or that have included Hispanics/Latinos, and that have estimated 
diabetes prevalence (8, 11–13, 54–61, 64, 65, 69–95). An analysis 
of the 2011–2012 NHANES cycle showed that the unadjusted 
prevalence of total diabetes based on ADA criteria (2-h OGTT, 
FPG, or HbA1c) was 14.3% (9.1% for diagnosed diabetes and 
5.2% for undiagnosed diabetes) and 38.0% for prediabetes (8). 
The prevalence of total diabetes for those of Hispanic/Latino 
heritage was twice as high (22.6%) than for NHWs (11.3%) and 
higher than the other racial/ethnic groups included in the study. 
The age-standardized prevalence of undiagnosed diabetes among 
Hispanic/Latino adults (49.0%) was significantly higher than that 
for NHWs (32.3%), and slightly lower than that for non-Hispanic 
Asians (50.9%) (8).
The baseline examination of the HCHS/SOL (2008–2011) 
showed that the prevalence of diabetes ranged from 10.2% in 
South Americans to 18.1% in Dominicans and Puerto Ricans 
and 18.3% in Mexicans (12). Prevalence by sex ranged from a 
low of 10.6% for South American men to a high of 18.7% for 
Mexican men, and from 9.8% in South American women to 
19.5% in Puerto Rican women. Diabetes prevalence increased 
significantly with age and BMI but was inversely associated with 
years of education and household income (12). Although the 
prevalence of diabetes also increased significantly with length of 
residence in the US, it was similar among US-born participants 
and foreign-born participants residing in the US for fewer than 
5 years. However, the prevalence was significantly higher among 
foreign-born participants with longer than 10 years of residence 
in the US. Nearly half of Hispanics/Latinos (48%) had adequate 
glycemic control, a rate slightly lower than those for NHWs 
(52.9%) and non-Hispanic Blacks (52.6%) who participated in 
the 1988–2010 NHANES cycles (96). Preliminary data from the 
second examination of the HCHS/SOL (2014–2017) demon-
strated an overall increase in prevalence of diabetes, which is still 
higher among Mexicans, Dominicans, and Puerto Ricans and 
lower among Cubans (97).
The HCHS/SOL also determined that nearly 40% of Hispanics/
Latinos with diabetes met at least one ADA criterion of undi-
agnosed diabetes (13). This finding is consistent with a recent 
NHANES data analysis that showed that Mexican Americans and 
other Hispanic women were more likely to be unaware of their 
diabetes status (98).
An additional analysis of HCHS/SOL baseline data found 
that 36.3% of the target population met at least one of the ADA 
criteria for prediabetes (97). Prevalence of prediabetes varied by 
age, sex, Hispanic/Latino heritage groups, and BMI categories, 
but was similar across place of birth and years living in the US. 
In the 2011–2012 NHANES cycle, the overall prevalence of 
prediabetes was 38.0%, and 36.8% for all Hispanics/Latinos (8).
Although there is a paucity of studies examining the preva-
lence of type 2 DM among children and adolescents, evidence 
suggests that prediabetes is highly prevalent among Hispanic/
Latino adolescents in the US. In a recent analysis based on 
the 2005–2014 NHANES cycles, the prevalence of prediabetes 
(based on FPG, 2hPG, or HbA1c) among all Hispanic/Latino 
adolescents (aged 12–19  years) was 22.9%. Among Mexican 
Americans it was 22.4%, significantly higher (P = 0.001) than in 
NHWs (15.1%) (94). Recent data from the Study of Latino Youth, 
a population-based cross-sectional study of 1,466 Hispanic/
Latino youth aged 8–16 years, found a combined prevalence of 
prediabetes and diabetes (based on FPG and HbA1c) of 16.5% 
TABLe 3 | Prevalence of type 2 diabetes and prediabetes among Hispanic/Latino populations in the US (selected studies).
Study 
(reference)
Study 
period
Sample size Age range 
(years)
Glycemic criteria Key findings
Puerto Rico  
Heart Health 
Program (54, 55)
1965–1980 2,567 rural and 6,190 urban 
Puerto Rican men
45–64 FPG ≥ 126 mg/dL, 
self-reports of physician-
diagnosed diabetes, 
or use of insulin or 
hypoglycemic agents
3.6% in rural men and 9% in urban men
Laredo  
Project (56)
1979 389 Mexican Americans 40–74 Fasting hyperglycemia 
defined as 
FPG > 140 mg/dL 
Age-adjusted prevalence was 10.9% in men and 10.1% 
in women
Starr County 
Study, Texas (69)
1981 2,498 Mexican Americans ≥15 Zero-hour (fasting) plasma 
glucose level ≥140 mg/dL 
or a 2-h level ≥200 mg/dL.
6.9% males and 6.7% females
Albuquerque,  
New Mexico (70)
1984–1985 1,175 Hispanics ≥18 Self-reported diagnosis Prevalence increased with age: men: 1.9% in  
25–34 to 13.8% in ≥75.
Women: 0.6% in 25–34 to 16.1% in ≥75
San Luis Valley 
Diabetes Study, 
Colorado (61, 71)
1984 607 Hispanics without prior 
history of DM
343 Hispanics with  
previously diagnosed DM
20–74 History of previously 
diagnosed DM with 
confirmation using 
FPG ≥ 140 mg/dL or 2-h 
OGTT ≥ 200 mg/dL
Age-adjusted prevalence of previously diagnosed DM: 
3.3% in men and 4.9% in women
Newly diagnosed DM: 2.2% in men and 4.3% in women
San Antonio Heart 
Study, Texas (57, 
58, 72)
First phase: 
1979–1982
Second 
phase: 
1984–1988
3,302 Mexican Americans 25–64 2-h OGTT Age-adjusted prevalence for men was 14.0% in the 
barrio vs. 6.5% in the suburbs and for men was 18.0% 
in the barrio vs. 4.3% in the suburbs.
Prevalence was two to three times higher in Mexican 
Americans than in NHWs.
Puerto Rico 
Household  
Health Interview 
Survey (73)
1975–1986 Minimum sample size  
of 2,696 in 1983
Maximum sample size of 
12,212 in 1976
All ages Self-reported diagnosis 3.1% in 1975 to 5.1% in 1986
4.5% of males and 5.8% of females reported a history 
of DM
HHANES (11) 1982–1984 6,588 Hispanics 20–74 years OGTT administered to 
subsample of 1,326
Cubans 45–74: 15.8%
Mexican Americans 45–74: 23.9%
Puerto Ricans 45–74: 26.1%
Cubans 20–44: 2.4%
Mexican Americans 20–44: 3.8%
Puerto Ricans 20–44: 4.1%
Mexico City 
Diabetes  
Study (74)
1979–1982 2,282 individuals of Mexican 
descent in San Antonio, and 
Mexicans in Mexico City 
35–64 FPG ≥ 126 mg/dL San Antonio: 17.8% in men and 23% in women
Mexico City: 12.3% in men and 18.5% in women
NHANES (75) 1999–2000 915
Mexican Americans, NHBs, 
and NHWs
12–19 IFG: 100–125 mg/dL Prevalence of IFG was 13.0, 4.2, and 7% in Mexican 
Americans, NHBs, and NHWs, respectively
NHANES (76) 1999–2002 1,802 adolescents without 
DM (672 Mexican American)
12–19 HOMA-IR Mexican American children had higher HOMA-IR levels 
than white children
NHANES (77) 1988–1994
1999–2002
1988–1994: 31,638 Mexican 
American, NHW and NHB 
adults
1999–2002: 17,217 Mexican 
American, NHW and NHB 
adults
≥20 Previously diagnosed DM
 Undiagnosed DM: 
FPG ≥ 126 mg/dL
IFG: 100–125 mg/dL
Among Mexican Americans:
Previously diagnosed DM: 9.6 and 10.6%
Undiagnosed DM: 4.7 and 3.5%
IFG: 32.9 and 33.0%
MESA (78) 2000–2002 1,437 Hispanics 45–84 FPG ≥ 126 mg/dL or 
use of hypoglycemic 
medication
Age-adjusted prevalence of diabetes
Mexican Americans: 22.3%
Dominicans: 16.1%
Puerto Ricans: 19.7%
Other Hispanics: 15.2%
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(Continued)
Study 
(reference)
Study 
period
Sample size Age range 
(years)
Glycemic criteria Key findings
NHANES (79) 2005–2006 2,806 Mexican American, 
NHW and NHB adults
≥20 FPG, OGTT Mexican Americans
Diagnosed DM: 12.6%
Undiagnosed DM: 7.5%
Total DM: 20.1%
Percent undiagnosed DM: 35.9%
Prediabetes: 32.0%
Prediabetes/DM: 52.0%
NHANES (80) 2005–2006 277 Mexican Americans
257 NHBs
198 NHWs
12–19 FPG and 2-h OGTT
ADA 1998
Prevalence of IFG, IFT, and prediabetes among Mexican 
Americans were 14.3, 3.5, and 16.9%, respectively
Study of Women’s 
Health Across  
the Nation 
(SWAN) (81)
1996–1997 3,302 women in seven 
sites; analysis based on 420 
women recruited in the New 
Jersey site
42–52 FPG ≥ 126 mg/dL or self-
reported use of insulin
3.3% in Caucasians, 5.9% in Dominicans, 8.3% in 
Central Americans, 9.8% in Cubans, 13.5% in Puerto 
Ricans, 15.6% in South Americans
Phase I of the 
US–Mexico 
Border Diabetes 
Prevention  
and Control 
Project (82)
2001–2002 4,027: 2,120 Hispanics from 
Mexico, 1,437 Hispanics 
from the US, and 470 non-
Hispanics from the US.
≥18 Self-reported diagnosis
FPG ≥ 126 mg/dL
Age-adjusted prevalence of self-reported and 
unrecognized DM was 16.6% of the Mexican side and 
14.7% on the US side; age-adjusted prevalence of IFG 
was similar on both sides of the border (14.1% on the 
Mexican side and 13.6% on the US side) 
BRFSS (83) 1995–2010 1995: 1,193 in Montana to 
5,107 in Maryland
2010: 1,964 in Alaska to 
35,109 in Florida
≥18 Self-reported diagnosis In 1995, age-adjusted prevalence was >6% in only three 
states, Washington, DC, and Puerto Rico.
In 2010, age-adjusted prevalence was highest (>10%) 
in Alabama, Mississippi, Puerto Rico, South Carolina, 
Tennessee, Texas, and West Virginia.
NHANES (85) 1999–2008 22,621 Mexican American, 
NHW and NHB adults, of 
whom 551 had undiagnosed 
DM
≥20 Undiagnosed DM was 
defined as HbA1c ≥ 6.5% 
without a self-report of 
physician-diagnosed DM
Overall prevalence of undiagnosed DM of 1.5% in 
NHWs, 3.1% in NHBs, and 2.7% in Mexican  
Americans
Overall prevalence of diagnosed DM of 6.7% in  
NHWs, 11.3% in NHBs, and 7.6% in Mexican 
Americans
California Health 
Interview  
Survey (86)
2001, 
2003, 
2005, and 
2007
33,633 Hispanics and 
126,488 NHWs
≥18 Self-report of physician-
diagnosed DM
Mexicans: 9%
Central Americans: 1%
South Americans: 0.5%
2 or more countries of origin: 7%
Other Hispanics: 13%
NHWs: 7%
NHANES (87) 1999–2002
2003–2006
2007–2010
19,182 Mexican American, 
NHW and NHB adults
≥12 HbA1c: 5.7–6.4%
FPG: 100–125 mg/dL
Prevalence of prediabetes among Mexican Americans: 
34.4, 30.3, and 37.8%
HCHS/SOL  
(12, 84)
2008–2011 16,415 Hispanics 18–74 FPG, 2-h OGTT, HbA1c Overall prevalence of DM was 16.9%
South Americans: 10.2%
Cubans: 13.4%
Central Americans: 17.7%
Dominicans: 18.1%
Puerto Ricans: 18.1%
Mexicans/Mexican Americans: 18.3%
SEARCH  
Study (88, 89)
2001–2009 3,345,783 youths in 2001 
and 3,458,974 in 2009
<20 Physician-diagnosed DM Prevalence of type 2 DM among Hispanic youth aged 
10–19 years was 0.45 per 1,000 in 2001 and 0.79 per 
1,000 in 2009, representing a relative increase of 76% 
over the 8-year period
NHANES (90) 1988–1994
1999–2004
2005–2010
1988–1994: 4,201
1999–2004: 2,860
2005–2010: 2,765
Mexican Americans
≥20 Based on HbA1c Diagnosed DM: 7.6 (0.57), 8.8 (1.06), 11.9 (1.01)
 Undiagnosed DM: 1.8 (0.17), 2.3 (0.40), 2.9 (0.32)
Prediabetes: 5.6 (0.64), 10.6 (0.68), 12.7 (0.76)
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TABLe 3 | Continued
Study 
(reference)
Study 
period
Sample size Age range 
(years)
Glycemic criteria Key findings
NHANES (8) 1988–2012 2011–2012: 2,623 (561 All 
Hispanics)
≥20 Self-reported diagnosis
Undiagnosed DM based 
on FPG, 2-h OGTT, 
HbA1c
All Hispanics
Total DM: 22.6%
Diagnosed DM: 12.5%
Undiagnosed DM: 10.1%
Prediabetes: 36.8%
Mexican Americans
Total DM: 23.8%
Diagnosed DM: 14.4%
Undiagnosed DM: 9.4%
Prediabetes: 38.0%
NHIS (91) 1997–2012 427,975 (367,292 non-
Hispanics and 60,683 
Hispanics)
≥18 Self-reported diagnosis Less than high school education: 17.6% for Puerto 
Ricans, 13.4% for Cubans, and 9.7% for Mexicans
High school diploma/GED: 9.8% for Puerto Ricans, 
8.2% for Cubans, and 6.3% for Mexicans
More than high school education: 6.8% for Puerto 
Ricans, 6.0% for Cubans, and 6.7% for Mexicans
HCHS/SOL (13) 2008–2011 15,507 Hispanics 18–74 FPG, 2-h OGTT, HbA1c 6.7% met at least one diagnostic criterion of  
probable DM – 39.4% of total DM (self-reported  
plus probable DM)
HCHS/SOL (92) 2012–2014 1,466 Hispanics 8–16 FPG and HbA1c
ADA 2015
Prevalence of prediabetes/DM was 16.5%, being higher 
in boys (20.9%) than in girls (11.8%)
Starr County, 
Texas (93)
2002–2014 5,230 Mexican American 
adults
≥20 FPG, OGTT, HbA1c Previously identified DM: 11.8% in men and 14.4% in 
women
Newly identified DM: 11.9% in men and 12.3% in 
women
Total DM: 23.7% in men and 26.7% in women
Prediabetes: 32.8% in men and 31.9% in women
NHANES (94) 2005–2014 2,606 NHWs, NHBs, and 
Hispanics
12–19 FPG, 2-h OGTT, HbA1c Prevalence of total DM, prediabetes, and percent 
undiagnosed DM:
All Hispanics: 0.76, 22.9, and 39.5%
Mexican Americans: 0.85, 22.4, and 43.9%
HCHS/SOL (95) 2008–2011 15,507 Hispanics 18–74 FPG, 2-h OGTT, HbA1c Prediabetes: 36.3%
Total IFG: 18.1%
Total IGT: 15.4%
Total impaired HbA1c: 21.2%
IFG + impaired HbA1c: 8.6%
IFG + IGT + impaired HbA1c: 3.8%
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TABLe 3 | Continued
(92), with boys having a higher prevalence compared with girls 
(20.9 vs. 11.8%, respectively). However, the study did not assess 
differences by Hispanic/Latino heritage group nor was OGTT 
available.
The limited number of studies examining the incidence 
of type 2 DM in Hispanic/Latinos (99–106) indicates that the 
incidence has been higher than in NHWs across all age groups 
(99–101) (Table 4). A recent analysis of type 2 DM in children 
examined in five study centers in the U.S (105) reported an 
annual rate increase significantly greater for Hispanics/Latinos 
(3.1%) compared to NHWs (0.6%), but significantly lower than 
Native Americans (8.9%). However, a recent analysis based on 
NHANES 2005–2014 cycle did not reveal an increase in inci-
dence in this age group (94).
A few studies have estimated GDM in Hispanics/Latinos 
(107–114) (Table  5). One of the early studies examining the 
epidemiology of GDM in an ethnically diverse cohort of over 
10,000 women at the Mount Sinai Medical Center in New York 
City between 1987 and 1990 found a prevalence of 3.2% (107). 
After controlling for traditional risk factors, first-generation 
Hispanic/Latino women had a 59% increased risk for GDM 
compared to NHW women. Kim et al. (112) found that among 
Hispanic/Latino women, the prevalence of GDM varied by her-
itage group, from 5.5% among Cubans to 8.7% among Mexicans. 
Nearly 45% of GDM cases among Hispanic/Latino women were 
attributable to overweight and obesity, which ranged from 
38.5% among Central/South American women to 65.7% among 
Cuban women. In a recent study of prevalence trends in GDM 
by race/ethnicity for 19 states, the GDM prevalence increased 
significantly from 3.71 per 100 deliveries in 2000 to 5.77 per 100 
deliveries in 2010 (113). Prevalence of GDM among deliveries 
increased significantly among all racial/ethnic groups, particu-
larly Hispanics/Latinas, who experienced the highest relative 
increase (66%).
TABLe 4 | Incidence of type 2 diabetes among Hispanic/Latino populations in the US (selected studies).
Study and 
reference
Study 
period
Sample size Age range 
(years)
Glycemic criteria Key findings
San Antonio Heart 
Study, Texas (99)
1979–1992 3,302 Mexican 
Americans
25–64 2-h OGTT 8-year incidence was 8.7% among Mexican Americans in the low-income 
barrio neighborhoods; 8.4% among Mexican Americans in the transitional 
neighborhoods; and 3.4% among Mexican Americans in the suburban 
neighborhoods
San Luis Valley 
Diabetes Study, 
Colorado (100)
1983–1988 607 Hispanics 
without prior 
history of DM
343 Hispanics 
with previously 
diagnosed DM
20–74 History of previously 
diagnosed DM with 
confirmation using 
FPG ≥ 140 mg/dL or 2-h 
OGTT ≥ 200 mg/dL
6-year incidence for Hispanic men and women was 4.3/1,000 and 
5.3/1,000, respectively; incidence was 2.4 (95% CI: 1.6–3.6) times higher 
in Hispanic men than in NHW men; incidence in Hispanic women was 3.6 
(95% CI: 2.4–5.4) times higher. 
San Antonio 
Heart Study, 
Texas (101)
1987–1996 1,995 Mexican 
Americans
1,231 NHWs
25–64 2-h OGTT ≥ 200 mg/dL
FPG ≥ 126 mg/dL
History of DM and 
receiving treatment 
with insulin or oral 
hypoglycemic agents
7- to 8-year incidence increased from 5.7% for Mexican Americans 
enrolled in 1979 to 15.7% for participants enrolled in 1988.
San Antonio 
Heart Study, 
and Mexico City 
Diabetes Study 
(102)
1987–1996 1,995 Mexican 
Americans
1,231 NHWs
35–64 2-h OGTT ≥ 200 mg/dL
FPG ≥ 126 mg/dL
History of DM and 
receiving treatment 
with insulin or oral 
hypoglycemic agents
6- to 8-year crude incidence was 90% higher in Mexican Americans 
men living in San Antonio than Mexicans in Mexico City: 2.70/100 versus 
1.42/100; in women, the crude incidence was more than twofold higher 
in San Antonio than in Mexico City: 2.86/100 versus 1.21/100. Incidence 
remained significantly higher in San Antonio than in Mexico City after 
adjusting for several confounders.
SEARCH for 
Diabetes in Youth 
Study, US (103)
2002–2005 635 incident 
cases from 
3,207,005 
Hispanic 
person-years 
at risk
<20 Physician-diagnosed DM Incidence of type 1 DM for youth aged ≤ 14 years was 15.0/100,000 
for females and 16.2/100,000 for males. Among youth aged ≤ 17 years, 
the rates of type 1 DM were 14.1/100,000 for females and 15.6/100,000 
for males. For type 2 DM, the rates were 6.9/100,000 for females and 
4.8/100,000 for males.
Puerto Rico Heart 
Health Program 
(104)
1965–1975 4,685 Puerto 
Ricans
35–79 FPG ≥ 126 mg/dL and 
self-reports of physician-
diagnosed diabetes or use 
of insulin or hypoglycemic 
agents
Crude rate of 11% over a median follow-up period of 2.6 years (range: 
2–7 years), for an incidence rate of 42.6/1,000 person-years.
New York City 
Community 
Health Survey 
(105)
2002, 
2004, and 
2008
24,384 ≥18 Self-reported DM Age-adjusted incidence of DM per 1,000 population was 9.4 in 2002, 
11.9 in 2004, and 8.6 in 2008. DM incidence was significantly associated 
with being aged 45 or older, being Black or Hispanic, being overweight or 
obese, and having less than a high school diploma.
SEARCH for 
Diabetes in Youth 
Study, US (106)
2002–2012 11,245 youths 
aged < 20 with 
type 1 DM and 
2,846 youth 
aged 10–19 
with type 2 
diabetes
<20 Physician-diagnosed DM Annual rate of increase in type 1 DM was greater among Hispanics than 
among NHWs (4.2 vs. 1.2%, P < 0.001). Annual rate of increase in type 
2 DM among Hispanics differed significantly from that among Native 
Americans (3.1% vs. 8.9%, P = 0.01). 
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Diabetes in Latin America
Table  6 illustrates selected studies assessing diabetes in Latin 
America (115–139). The prevalence of diabetes varies by date in 
which the studies were performed, methods of assessing preva-
lence, region and age group (140, 141).
According to a 2015 International Diabetes Federation 
report, the prevalence of type 2 DM in Latin America was high-
est in Mexico (14.7%) and lowest in Argentina (6.2%); how-
ever, over one-quarter of the Latin American and Caribbean 
population remained undiagnosed (141). The Cardiovascular 
Risk Factor Multiple Evaluation in Latin America (CARMELA) 
Study (conducted between 2003 and 2005) (128) reported 
an age-adjusted prevalence of diabetes of 7.0% in seven urban 
populations in Latin America (129). The prevalence was highest 
in Mexico City, Mexico (8.9%) and Bogotá, Colombia (8.1%) 
and lowest in Lima, Perú (4.4%); it increased with age in all 
cities, and tended to be higher among women than men. 
Prevalence of undiagnosed diabetes occurred in 20% of adults 
with diabetes. The Latin American Consortium of Studies in 
Obesity (LASO) (which included 11 studies conducted in eight 
countries between 1999 and 2008) (132) reported an average 
prevalence of 5%, which increased from 0.9% in participants 
aged 20–29  years to 16.4% in those aged 70 or older (133). 
However, the prevalence of diabetes in Latin America and 
TABLe 5 | Incidence or prevalence of gestational diabetes mellitus among Hispanic/Latino populations in the US.
Study and reference Study 
period
Sample size Age range 
(years)
Glycemic criteria Key findings
New York City (107) 1987–1989 10,187 (328 with 
GDM; of these 
112 Hispanic)
<20 to ≥40 FPG and OGTT according to 
National Diabetes Data Group
Prevalence of 4.1% among Hispanics Excess risk for 
Hispanic women born in Puerto Rico or elsewhere 
outside of the US
Nurses’ Health Study II 
(108)
1990–1994 14,613 (224 
Hispanic)
25–42 Self-reported GDM, validated 
by medical record review in a 
subset
4.7% Whites, 10.6% AAs, 7.6% Hispanics, and 10.5% 
Asians
Northern California Kaiser 
Permanente Medical Care 
Program (109)
1991–2000 267,051 
pregnancies 
screened for GDM
15–49 Physician diagnosis or ADA 
criteria
Age- and race/ethnicity-adjusted yearly prevalence 
increased from 5.1% in 1991 to 7.4% in 1997, being 
significantly higher among Asians (7.2–11.0%) and 
Hispanics (7.2–9.8%)
New York City (110) 1995–2003 951,920 15–44 Diagnostic codes ICD–9 
648.81–648.82
Overall risk of 5.2%
7.2% North African
5.9% Sub-Saharan Africa
6.2% East Asia
8.6% South-East Asia and Pacific Islands
14.3% South Central Asia
6.8% Non-Hispanic Caribbean
4.9% Hispanic Caribbean
6.3% Mexico
4.9% Central American
6.6% South American
34.3% African-American
3.6% NHWs
19 US states (111) 2005–2006 3,108,877 births <20 to ≥40 Documented in birth certificate 3.8% NHWs, 3.5% NHBs, 3.6% Hispanics, 6.3% Asian, 
and Pacific Islanders
California (112) 2007–2009 1,228,265 records ≥20 ICD-9-CM codes for 
pregestational DM (250) or DM 
(648.0)
GDM was defined as glucose 
intolerance complicating 
pregnancy, childbirth, or 
postpartum (ICD-9-CM  
code 648.8).
11.9% Asian and Pacific Islands, 7.6% American Indians, 
5.6% Black Americans, 8.4% Hispanics, 6.6% others, 
and 5.4% NHWs
Among Hispanic women: Mexican (8.7%), Central/South 
American (7.4%), Puerto Rican (6.6%), and Cuban (5.5%)
GDM among hospital 
deliveries in 19 US states 
(113)
2000–2010 75,212 in 2000 to 
119,229 in 2010
15–44 ICD-9-CM 648.8x, DRG codes 
767–768, 774–775, and 
765–766 (2008–2010),  
or DRG codes 370–375  
(2000–2007)
Age-standardized prevalence increased from 3.71% in 
2000 to 5.77% in 2010
Largest relative increase in prevalence was highest 
among Hispanics (66%)
Prepregnancy diabetes 
among deliveries in 19 US 
states (114)
2000–2010 13,217 in 2000 to 
18,168 in 2010
15–44 ICD-9-CM 648.0x. 250.
xx, or 249.xx or DRG codes 
767–768, 774–775, and 
765–766 (2007–2010) or DRG 
codes 372–375 (2000–2007)
Age-standardized prevalence of deliveries with 
prepregnancy DM among Hispanics ranged from 0.74 in 
2000 to 0.94 in 2010
NHBs, followed by Hispanics, had the highest absolute 
change in age-standardized rates (0.20 per 100 
deliveries) and throughout the time period had the 
highest rates of prepregnancy DM
ICD-9, International Classification of Diseases, Ninth Version; ICD-9-CM, International Classification of Diseases, Ninth Version, Clinical Modification. DRG, Diagnosis-Related Group.
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the Caribbean was similar to the US population (NHANES, 
1999–2004), after accounting for differences in the age dis-
tribution. Puerto Rico had the highest prevalence among the 
countries included in the analysis.
More recent Latin American studies include the Estudo 
Longitudinal de Saúde do Adulto (ELSA-Brasil) (134), which 
reported a prevalence of 19.7% (based on self-report or FPG, 
2hPG and HbA1c), of which about half was undiagnosed (135); 
the Centro de Excelencia en Salud Cardiovascular para el Cono 
Sur I (CESCAS I), which reported an overall prevalence (based 
on FPG only) of 12.4% across four sites in Argentina, Chile, and 
Uruguay (136); and the Centro de Excelencia de Enfermedades 
Crónicas (CRONICAS), which reported an overall prevalence of 
7.1% (based on FPG only) across four regions in Perú (139).
One of the few studies in Latin America and the Caribbean that 
estimated the incidence of type 2 DM is the Mexico City Diabetes 
Study, which focused on the population aged 35–64 years over 
18  years of follow-up (143) (Table  7). Cumulative incidence 
rates of type 2 DM for men and women were 14.4/1,000 and 
13.7/1,000, respectively. Incidence was 15.8, 15.7, and 12.7 per 
TABLe 6 | Prevalence of type 2 diabetes and prediabetes among Hispanic/Latino populations in Latin America (selected studies).
Study and reference Study 
period
Sample size Age range 
(years)
Glycemic criteria Key findings
The Brazilian Cooperative Group  
on the Study of Diabetes 
Prevalence (115)
1986–1988 21,847 from nine large 
cities
30–69 2-h OGTT
WHO 1985
Overall prevalence was 7.6 and 7.8% 
for diabetes and IGT, respectively. DM 
prevalence increased from 2.7% in the 
30–39-year age-group to 17.4% in the 
60–69-year age-group
The Cooperative Group for the 
Study of Diabetes Prevalence  
in Rio de Janeiro, Brazil (116)
1988–1989 2,051 30–69 2-h OGTT
WHO 1985
Age-adjusted prevalence rates for DM 
and IGT were 7.1 and 9.0%, respectively
Bolivia (117) 1998 2,948 from four Bolivian 
cities: La Paz, El 
Alto, Santa Cruz, and 
Cochabamba
≥25 2-h OGTT
WHO 1997
Overall prevalence of DM was 7.2% and 
of IGT was 7.8%.
Brazilian Multicenter Study, Ribeirão 
Preto, São Paulo, Brazil (118)
1986–1988 1,473 30–69 2-h OGTT
WHO 1997
The overall rates of DM and IGT were 
12.1 and 7.7%, respectively
Mexican National Health Survey 
2000 (119)
2000 42,886 from 400 cities 
in Mexico
≥20 2-h OGTT
FBG
ADA 1997
Age-adjusted prevalence 8.2%, of 
which 2,878 (80%) had previously been 
diagnosed.
Argentina (120) 1995–1998 2,397 ≥20 2-h OGTT
WHO 1999
Age-standardized prevalence rates for 
diabetes ranged between 6.5 and 7.7%
Mexican National Health Survey 
2000 (121)
2000 12,856 men and  
28,332 women
20–69 2-h OGTT
FBG
ADA 1997
DM rates of 5.6% in men and 9.7% in 
women
The Health Wellbeing and Aging 
(SABE) Project and NHANES (123)
1999–2004 10,518 ≥60 Self-reported diagnosis 13.0% in Santiago, 13.8% in Montevideo, 
14.7% in Havana, 17.7% in São 
Paulo, 21.3% in Mexico City, 21.7% in 
Bridgetown
US Whites 13.8%
US Blacks 25.5%
US Mexican Americans 26.4%
The Health Wellbeing and Aging 
(SABE) Project (124)
1999–2000 13,753 ≥60 Self-reported diagnosis Prevalence of diagnosed diabetes was 
highest in US Blacks and Mexican 
Americans, followed by Bridgetown and 
Mexico City (22% for each) and lowest in 
Santiago, Montevideo, Havana, and US 
Whites (13–15%).
The FRIMEX Study (125) 2001–2002 140,017 from 6 Mexican 
cities: Mexico City, 
Guadalajara, Monterrey, 
Puebla, Leon, and 
Tijuana
≥18 FBG > 126 mg/dL
Random > 200 mg/dL
Prevalence of 10.4%
PREVENCION
Peruvian Study of the Prevalence  
of Cardiovascular Diseases (126)
2004–2006 1,878 adults in 
Arequipa, Peru 
20–80 FPG ≥ 100 mg/dL or current 
antidiabetic medication 
(insulin or oral agents) 
Age-standardized prevalence was 6.3% 
in men and 5.9% in women
Pelotas, Rio Grande do Sul State, 
Brazil (127)
2003 3,100 men  
and women
≥20 Self-reported diagnosis Prevalence of DM of 6.3%
CARMELA Study (128) 2003–2005 11,550 in 7 Latin 
American countries
25–64 FPG ≥ 126 mg/dL or self-
reported diagnosis
Prevalence of DM was 7% (range: 4–9%)
CARMELA Study (129) 2003–2005 11,502 in 7 Latin 
American countries
25–64 FPG ≥ 110 mg/dL or self-
reported diagnosis
31.2% had glucose abnormalities (32.6% 
of men and 30.1% of women)
Mexico City Prospective  
Study (130)
1998–2004 52,584 men and 
106,962 women
≥35 Self-reported diagnosis 4.8% in men and 3.9% in women
Chile (131) 2000–2005 486 overweight and 
obese adolescents
6–15 FPG ≥ 100 mg/dL 2% in males Tanner stage I-II
1% in females Tanner stage I-II
9% in males Tanner stage III-V
6% in females Tanner stage III-V
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(Continued)
TABLe 7 | Incidence of type 2 diabetes and gestational diabetes mellitus among Hispanic/Latino populations in Latin America.
Study and reference Study 
period
Sample size Age range 
(years)
Glycemic criteria Key findings
Brazilian Gestational 
Diabetes Study (142)
1991–1995 4,977 ≥20 years OGTT
ADA 2000
WHO 1999
2.4% presented with GDM by ADA criteria and 7.2% by WHO criteria.
Mexico City Diabetes 
Study (143)
1990–2008 1,939 35–64 OGTT
ADA criteria
Cumulative incidence was 14.4/1,000 and 13.7/1,000 for men and 
women, respectively.
Incidence was 15.8/1,000, 15.7/1,000, and 12.7/1,000 for the second 
(1994), third (1998), and fourth (2008) follow-up phases, respectively.
CRONICAS Cohort 
Study (139)
2010–2013 3,135
Four Peruvian 
sites
≥35 FPG ≥ 126 mg/dL or 
self-reported current 
pharmacological 
treatment
Overall incidence of 1.95 per 100 person-years.
1.97 per 100 person-years in women and 1.93 per 100 person-years 
in men.
Study and reference Study 
period
Sample size Age range 
(years)
Glycemic criteria Key findings
The Latin American Consortium of 
Studies in Obesity (LASO) (133)
1998–2007 31,009
Argentina, Chile, 
Colombia, Costa Rica, 
Dominican Republic, 
Perú, Puerto Rico, and 
Venezuela
20–85 FPG ≥ 126 mg/dL or 
self-reported current 
pharmacological treatment
Average prevalence of 5%, 4.8% in 
women and 5.1% in men
Puerto Rico had a significantly higher 
prevalence of DM
Brazilian Longitudinal Study of 
Adult Health (ELSA-Brasil) (135)
2008–2010 15,105 35–74 Self-reported diagnosis, 
medication use, 
FPG ≥ 126 mg/dL, 2-h 
post-OGTT ≥ 200 mg/dL, or 
HbA1c ≥ 6.5%
Prevalence of DM was 19.7%
Proportion of previously diagnosed DM 
was 50.4%
CESCAS [Centro de Excelencia en 
Salud Cardiovascular para el Cono 
Sur] I Study (136)
2010–2011 7,524
Argentina, Chile, and 
Uruguay
35–74 FPG ≥ 126 mg/dL or self-
reported history of diabetes
Prevalence of DM of 12.4%, 10.6% in 
men, and 14% in women
Panama Survey of Life and Health 
Quality (ENSCAVI) and Survey 
of Risk Factors Associated 
with Cardiovascular Diseases 
(PREFREC) (137)
2007
2010–2011
25,748
3,590
≥18
≥18
Self-reported diagnosis of 
diabetes
FPG ≥ 126 mg/dL and 
HbA1c ≥ 6.5%
Prevalence of DM of 5.4%
Prevalence of previously diagnosed DM of 
7.3% and combined prevalence of DM of 
9.5% based on FPG and HbA1c
Multiethnic Study of Pre-Diabetes 
and Diabetes in LMIC (138)
2010–2011 23,496
Southern Cone of Latin 
America, Peru, South 
Asia, and South Africa.
≥20 Diabetes: FPG ≥ 126 mg/dL
Prediabetes: 100–125 mg/dL 
Prevalence of DM and prediabetes 
was 14.0 and 17.8%, respectively, in 
the Southern Cone of Latin America; 
estimates were 9.8 and 17.1%, 
respectively, in Perú.
CRONICAS
Centro de Excelencia de 
Enfermedades Crónicas Cohort 
Study (139)
2010–2013 3,135
Four Peruvian sites
≥35 FPG ≥ 126 mg/dL or 
self-reported current 
pharmacological treatment
Overall prevalence of 7.1%
FBG, fasting blood glucose.
1,000 person-years for the follow-up studies conducted in 1994, 
1998, and 2008, respectively. These figures suggest that this popu-
lation has one of the highest diabetes incidence rates worldwide, 
and that incidence rates have remained fairly stable.
Other Cv Risk Factors in Hispanics/
Latinos
Overweight/Obesity
In the most recent NHANES examination (2013–2014 cycle), 
the age-adjusted prevalence of obesity in adults (>20  years) 
was 37.1% for NHWs and 42.7% for Hispanics/Latinos, with 
Hispanic/Latino men and women having 21% and 33% increased 
odds of obesity compared to NHWs, respectively (144). In the 
most current NHANES examination, the prevalence of obesity in 
children was 14.7% for NHWs and 21.9% in Hispanics/Latinos, 
and extreme obesity was 4.4% in NHWs and 7.6% in Hispanics/
Latinos (145). In the baseline examination (2008–2011) of the 
HCHS/SOL, 77% of participants had overweight or obesity, 
and the age-adjusted prevalence of obesity ranged from 26.8% 
in South American men to 51.4% in Puerto Rican women (84). 
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However, enlarged waist circumference (≥102  cm in men and 
≥88 cm in women) was highly prevalent among men (73%) and 
women (96%), independent of the heritage group (146). A higher 
prevalence of overall obesity in women compared to men, and 
high prevalence of abdominal obesity have also been described 
in Puerto Rico (147, 148).
The CARMELA study reported an overall obesity preva-
lence of 23%, ranging from 16% in Quito, Ecuador to 31% in 
Mexico City, Mexico (128). The LASO reported that overall 
obesity ranged from 13.8% in men to 18.4% in women, and 
that abdominal obesity ranged from 15.4% in men to 55.5% 
in women (133). CESCAS I reported a prevalence of 35.7% 
obesity and 52.9% central obesity (136), whereas CRONICAS 
reported a prevalence of 44.0% overweight and 26.0% obesity 
among individuals without diabetes, and 40.8% overweight 
and 39.9% obesity among those with diabetes; and enlarged 
waist circumference in 71.5% without diabetes and 88.5% 
with diabetes (139); and in ELSA-Brasil, 40.2 and 22.9% had 
overweight and obesity, respectively (149). Although the 
prevalence of obesity in some regions of Latin America has 
been lower than that of Hispanics/Latinos in the US, in others 
it is comparable.
A systematic review of studies published between 2008 and 
2013 estimated that the prevalence of overweight and obesity for 
children and adolescents throughout Latin America ranged from 
18.9 to 36.9% in children aged 5–11 and 16.6 to 35.8% in adoles-
cents aged 12–19 (150). An obesity trend analysis from Mexico 
(2012) revealed a significant increase during the same time frame 
in which obesity increased in the US (145, 151). The prevalence 
of overweight/obesity also increased in Colombia from 38.2% in 
2000 to 43.1% in 2010 (152).
Hypertension
In the 2009–2010 NHANES cycle, the age-adjusted prevalence of 
hypertension among US adults was 29.8% for NHW men, 26.9% 
for NHW women, 26.3% for Mexican American men, and 27.7% 
for Mexican American women (153). In the HCHS/SOL, the age-
adjusted prevalence of hypertension was 25.5% (154).
In CARMELA, hypertension prevalence ranged from 7.2% 
(men) and 10.1% (women) in Ecuador to 37.7% (men) and 21.7% 
(women) in Argentina (155). LASO reported a mean prevalence 
of 20.2% (133). CRONICAS reported a prevalence of 23.9% for 
individuals without diabetes, and 50.9% for individuals with 
diabetes (139). ELSA-Brasil reported a mean prevalence of 25.7% 
in women and 34.5% in men (149). In CESCAS I hypertension 
prevalence ranged from 36.9% in Temuco, Chile to 45.3% in 
Bariloche, Argentina, and a mean of 40.8% in Chile, Argentina, 
and Uruguay (136).
Dyslipidemia
In the 2011–2012 NHANES cycle, prevalence of high total cho-
lesterol was 13.5% in NHWs and 14.2% in Hispanics/Latinos, 
and the prevalence of low high-density lipoprotein cholesterol 
(HDL-C) was 17.1% in NHWs and 21.8% in Hispanics/Latinos 
(156). In the HCHS/SOL, the prevalence of elevated total 
cholesterol was 13.9% in women and 14.3% in men, elevated 
low-density lipoprotein cholesterol (LDL-C) was 34% in women 
and 38.2% in men, triglycerides (TGs) > 200 mg/dL was 10.2% in 
women and 19.8% in men, and low HDL-C was 47.9% in women 
and 34.3% in men (157).
In CARMELA, the prevalence of hypercholesterolemia ranged 
from 5.7% in Barquisimeto, Venezuela to 20.2% in Quito, Ecuador 
(128). CESCAS I reported an overall prevalence of hypercho-
lesterolemia of 24.4% (which ranged from 20.8% in Bariloche, 
Argentina to 31.0% in Barros Blancos, Uruguay), high LDL-C of 
23.1%, low HDL-C of 34.1%, and hypertriglyceridemia of 22.1% 
(136). LASO reported an overall prevalence of 8.9% of elevated 
total cholesterol, 8.5% of high LDL-C, 53.3% of low HDL-C, and 
26.5% of high TGs (133). ELSA-Brasil reported a mean preva-
lence of hypercholesterolemia of 68.2% in women and 65.5% 
in men (149). Although the prevalence of lipid and lipoprotein 
abnormalities varies by region and study, it seems like low HDL-C 
is highly prevalent across Hispanic/Latino populations in the US 
and Latin America.
Tobacco Use
The prevalence of smoking among US adults is 16.7% for men and 
13.6% for women, with distinct racial/ethnic differences (158). 
The prevalence among NHWs is 20.2%, and 10.1% for Hispanics/
Latinos, nationwide. However, the HCHS/SOL demonstrated a 
higher overall prevalence of daily smoking (16.9% in men and 
10.7% in women) and significant differences among heritage 
groups with higher prevalence of daily smokers in Puerto Rican 
men (27.0%), Cuban men (26.2%) and Puerto Rican women 
(24.2%), and lower smoking prevalence in Dominican men 
(8.8%) and Mexican women (4.4%) (159).
In Latin America, the CARMELA reported a prevalence 
of current smoking that ranged from 21.8% in Barquisimeto, 
Venezuela to 45.4% Santiago, Chile (128). LASO reported a 
mean prevalence of 25.8% (133), and CESCAS I reported a mean 
prevalence of 29.7% in Argentina, Chile, and Uruguay (136). 
ELSA-Brasil reported a mean prevalence of current smoking of 
15.5% in women and 16.7% in men (149). In contrast, CRONICAS 
reported a prevalence of daily smoking of 3.3% among 
individuals without diabetes, and 2.7% among those with diabetes 
in Perú (139).
Behavioral Risk Factors
Cardiometabolic factors are influenced by modifiable behav-
ioral risk factors, namely physical activity (PA), and dietary 
intake. The 2010 Racial and Ethnic Approaches to Community 
Health Risk Factor Survey estimated approximately one-third 
of Hispanic/Latino men and women met PA recommendations 
(160). Moreover, using objective measures, the HCHS/SOL 
reported that Hispanic/Latino adults spent 11.9 h/day, or 74% of 
their monitored time, in sedentary behaviors, with less time for 
Mexicans and more for Dominicans (161). CESCAS I reported 
a prevalence of physical inactivity of 35.2% (136); ELSA-Brasil 
reported a mean prevalence of physical inactivity of 79.8% in 
women and 70.9% in men (149).
In the HCHS/SOL, differences in total energy, macronutrient, 
and nutrient-dense intakes were observed among the different 
heritage groups (162), with higher total energy and macronutri-
ent intakes by Cubans, higher fiber intake by Mexicans, lower 
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fiber intake by Puerto Ricans and lowest total energy intake by 
Dominicans. Evaluations of the dietary intake and quality based 
on the 2010 Alternate Health Eating Index and the Dietary 
Approaches to Stop Hypertension (DASH) revealed overall low 
scores for intakes of whole grains, and fruit and vegetables with 
lower dietary quality for Puerto Ricans and higher quality for 
Mexicans (163, 164).
Dietary patterns in Latin America have been gradually 
shifting toward increased consumption of sugars and meat, and 
decreased consumption of fruit and cereals across the continent 
(165, 166). In CESCAS I, 85.5% of participants reported low 
intake of fruits and vegetables (136). CRONICAS reported that 
3.8% of individuals without diabetes and 9.5% with diabetes 
consumed 5 or more servings of fruits/vegetables per day (139). 
ELSA-Brasil reported low health dietary scores (1.23–1.38 out 
of 5) (149).
eTiOLOGY OF TYPe 2 DM iN HiSPANiCS/
LATiNOS
Multiple factors contribute to type 2 DM risk including: genetic 
variations, demographic characteristics, and behavior- and 
lifestyle-related risk factors (167). Among the pathophysiologic 
defects in type 2 DM, insulin resistance along with β-cell failure 
are considered major defects (168). Alterations in the adipose 
tissue (endocrine organ), the gut incretin-system (enteroinsular 
axis), renal reabsorption of glucose, and brain insulin response 
also play important roles in the development of glucose intoler-
ance and type 2 DM (169). In addition, alterations in the crosstalk 
between immune and metabolic pathways are closely linked to 
obesity and diabetes (170). Inflammation is also recognized as 
a common pathway for the major complications of atheroscle-
rosis, stroke, and ischemic heart disease, commonly observed 
in persons with diabetes (171). Some of these aspects have been 
studied in Hispanics/Latinos.
Obesity and insulin Resistance
As reported in other ethnic groups, type 2 DM is associated with 
obesity in Hispanics/Latinos (172). However, obesity does not 
explain the excess diabetes prevalence among Hispanics/Latinos 
compared to NHWs (172). For instance, 29.3% of participants 
of HCHS/SOL with prediabetes had normal weight (95). On the 
other hand, duration of obesity or earlier age of onset has been 
associated with increased risk of developing type 2 DM (173–175).
In addition to overweight or obesity, the distribution of the 
adipose tissue has been associated with increased risk for type 2 
DM and CVD. Non-alcoholic hepatic steatosis, for example, has 
been described in some Hispanic/Latino groups, and has been 
linked to increased insulin resistance and other cardiometabolic 
abnormalities (176, 177).
Data from the SAHS showed that insulin resistance measured 
by several insulin resistance surrogates accounts for a significant 
proportion of the excess type 2 DM risk in Mexican-Americans 
compared to NHWs (178). This study also showed evidence of 
higher all-cause and CV mortality among Hispanics/Latinos 
born in the US (179).
Adipokines, Hypercoagulability, 
inflammation, and endothelial Dysfunction 
Biomarkers
Several adipokines and inflammation and hypercoagulability 
mediators, such as leptin, intercellular adhesion molecule-1, tis-
sue plasminogen activator, inhibitor of plasminogen activator-1, 
high-sensitivity C-reactive protein (CRP), macrophage chemoat-
tractant protein 1 (MCP-1), tumor necrosis factor (TNF)-α, and 
interleukin-6 (IL-6) have been found to be elevated in young 
Hispanics/Latinos at high risk of developing type 2 DM (180–189) 
and individuals from different racial/ethnic groups—including 
Hispanics/Latinos—with type 2 DM (189–194). Elevated IL-6, 
leptin, CRP, and TNF-α have been observed in Mexican Americans 
with type 2 DM, and the elevation IL-6 and leptin in particular 
was linearly associated with increasing glycemia (194).
For example, in a prospective study of Hispanic/Latino 
adolescents with obesity, higher baseline MCP-1 or IL-6 levels at 
prepubertal age were associated with a 16 and 21% greater decline 
in insulin sensitivity during puberty (195). However, this relation-
ship between proinflammatory/endothelial dysfunction markers 
and insulin sensitivity has been shown to vary with adipose tissue 
distribution, and may differ across racial/ethnic groups (188, 192). 
Adiponectin, a collagen-like protein secreted from adipose tis-
sue has been inversely correlated with both insulin sensitivity 
and adiposity (196–198), and increased risk of developing type 
2 DM in Hispanic/Latino adults (199). Adiponectin inversely 
correlates with CV risk factors in older adults (200), and appears 
to predict progression to glycemic failure in adolescents with type 
2 DM from different ethnic groups (200, 201). A cautionary note: 
Most of these studies have been small, and the representation of 
Hispanic/Latino heritage groups has been very limited.
Other Factors
Maternal factors such as fasting indexes of total triiodothy-
ronine, insulin, leptin, and ghrelin have been associated with 
excessive weight gain in Hispanic/Latino children (202–204). 
Women who experience GDM are at high risk of developing 
GDM in subsequent pregnancies (205, 206) and type 2 DM 
(205). In addition, children born to women with GDM are at 
increased risk of obesity and glycometabolic disease later in life 
(204–214). Increased proinflammatory markers have also been 
identified in women with GDM (215). Research studies involv-
ing Hispanic/Latino women in the US or in Latin America have 
described increased proinflammatory markers (e.g., proinflam-
matory cytokines and/or natural killer cells) at the placental 
level (216–218), and at both the placental and fetal level (219) 
associated with maternal hyperglycemia during pregnancy. In 
Mexican women, prepregnancy overweight and obesity have 
been associated with increased oxidative stress in the newborn 
(220). In Chile, in women with overweight or obesity and GDM, 
maternal elevated TGs were associated with increased infant’s 
birth weight (BW), despite good maternal glucose control (221). 
Maternal hyperglycemia, whether due to preexisting diabetes 
or GDM, has been associated with increased oxidative stress 
and maternal DNA damage (222, 223), and both placental and 
umbilical cord DNA damage (222, 223). However, the number 
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of patients in these studies has been small, and the interaction 
of obesity or other proinflammatory factors cannot be separated 
from hyperglycemia. Whether these changes could be prevented 
or reversed is unknown.
Low BW, like maternal GDM, has been inversely associated 
with glucose intolerance and insulin sensitivity during child-
hood and increased risk for CVD later in life. This susceptibil-
ity to adult chronic diseases may be a response to exposures 
in utero—known as fetal programming—or early malnutrition 
in extra uterine life (224, 225). Several studies in Latin America 
have documented the inverse association between BW and 
insulin sensitivity later in life (226), malnutrition during the first 
year of life and insulin sensitivity, glucose tolerance and meta-
bolic syndrome later in life (227–229); and being exclusively or 
predominantly breastfed > 12 months and lower adiposity and 
serum cholesterol during childhood (230).
Chronic malnutrition is associated with alterations in glucose 
metabolism and insulin sensitivity (231). Decades ago, a malnu-
trition-modulated diabetes or tropical diabetes was described in 
developing countries (232, 233). Some investigators hypothesized 
that consumption of cassava (manioc or tapioca) could lead to 
diabetes in malnourished subjects, due to cyanogenic glycosides 
leading to chronic pancreatitis; however, the theories remained 
largely speculative (232). Others postulated that chronic protein 
energy malnutrition would cause persistent insulin deficiency 
and glucose intolerance without ketosis, among other clinical 
features (234–236).
A link between plasma branched-chain amino acids (BCAAs) 
and insulin clearance has been observed in recent years. Over-
weight persons exposed to a diet high in saturated fat have been 
found to have a significant inverse correlation between plasma 
BCAAs and insulin clearance. This association has also been 
observed in Hispanics/Latinos (237).
Atypical forms of diabetes such as ketosis prone diabetes (KPD) 
have also been described in Hispanics/Latinos. KPD affects 
20–50% of African-American and Hispanic/Latino patients with 
new diagnoses of diabetic ketoacidosis (238). Hispanics/Latinos 
with KPD also appear to be disproportionally affected by KPD 
characterized by an absence of autoantibodies and presence of 
β-cell functional reserve (239, 240).
Sleep disruptions characteristic of obstructive sleep apnea 
(OSA) and that alter sleep duration and timing may promote 
behavioral, metabolic, and/or hormonal changes associated with 
changes in weight (241–244). OSA is independently associated 
with insulin resistance (245) and predicts subsequent risk for type 
2 DM (246). In the HCHS/SOL, both quantity and quality of sleep 
were associated with higher odds of having type 2 DM (247, 248) 
and impaired glucose tolerance (IGT) (247) with the greatest odds 
among those with short sleep duration and insomnia (249). Three 
loci have been found to be significantly associated with OSA traits 
in a large genome-wide association study of 12,558 Hispanics/
Latinos (250). The association of fasting blood glucose and OSA 
was weaker among Hispanics/Latinos in MESA compared to 
African Americans (AA) and NHWs (251).
In recent years, Alzheimer’s disease (AD) has been considered 
as a metabolic disease mediated by alterations in brain insulin 
responsiveness, glucose utilization, and energy metabolism that 
can lead to increased oxidative stress, inflammation, and wors-
ening insulin resistance (252). The association between type 
2 DM and AD has been called type 3 diabetes (253). Mexican 
American elders with diabetes are at almost twofold increased 
risk of dementia than those without diabetes (254). Also, longer 
duration of diabetes has been associated with a faster rate of 
cognitive decline in this age group (255). Further research is 
needed to examine the interaction of type 2 DM and AD in this 
vulnerable group, and among other Hispanic/Latino groups.
Other emerging risk factors for type 2 DM and CVD include 
the gut microbiome (256–258), gallbladder disease (259), 
environmental exposures (260–262), and the impact of sugar-
sweetened beverages intake on satiety (263). Research on these 
emerging factors in Hispanics/Latinos has been limited.
Genetics and Type 2 DM in Hispanics/
Latinos
The polygenic nature of type 2 DM is well established and more 
than 100 loci for type 2 DM and glycemic traits have been 
identified through genome-wide association studies (GWAS) of 
common and rare variation in populations of diverse ancestral 
origins (264).
Genetic variations in the gene encoding for transcription 
factor 7-like 2 (TCF7L2) have been associated with type 2 DM 
in different populations (265). The T allele of single nucleotide 
polymorphism (SNP) rs7903146 of TCF7L2 strongly predicts the 
development of type 2 DM (265, 266). TCF7L2 has been associ-
ated with GDM and type 2 DM in Hispanics/Latinos of Mexican 
descent (267, 268), and polymorphisms of this gene have been 
associated with reduced acute insulin response in this heritage 
group (269). This gene has also been associated with diabetes in 
the HCHS/SOL (270). TCF7L2 polymorphism rs7903146 has 
also been associated with coronary artery disease (271, 272) and 
stroke (273) among patients with long standing history of type 
2 DM.
A haplotype containing four missense SNPs, all in SLC16A11, 
conferring 20% increased risk for type 2 DM was identified 
through GWAS in Mexican and other Latin American samples 
in the SIGMA type 2 DM Consortium (274). A newly identi-
fied African ancestry-specific allele at KCNQ1 was associated 
diabetes in HCHS/SOL (270), however, the mechanisms lead-
ing to type 2 DM due to alterations in this allele are less well 
understood (275).
Whole-exome sequencing in 3756 individuals of Mexican and 
Mexican American ancestry identified a rare variant (p.E508K) in 
HNF1A that had significant association (fivefold increase) with 
type 2 DM (276). HNF1A is the gene responsible for MODY3, 
a monogenic, early-onset form of type 2 DM, however carriers 
of p.E508K did not show early-onset of type 2 DM and were 
indistinguishable from the wider type 2 DM population, thus not 
fulfilling the classical diagnostic criteria for MODY3 (276).
The Genetics Underlying Diabetes in Hispanics/Latinos 
(GUARDIAN) Consortium (277) conducted a GWAS in multiple 
Mexican-ancestry cohorts with highly detailed glucose homeo-
stasis measures. Nonparametric meta-analysis of the Discovery 
and Translation cohorts identified a significant relationship with 
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type 2 DM phenotype at 6p24 (SLC35B3/TFAP2A) in associa-
tion with glucose effectiveness, 11p15 (KCNQ1) with disposition 
index, and 6p22 (CDKAL1) and 11q14 (MTNR1B) with acute 
insulin response (277).
Genetic studies of GDM in Latin American women have 
yielded varied findings. In Brazilian women, GDM has been 
associated with the glucokinase gene (278), the MTNR1B gene 
polymorphism rs10830963 (279), LGALSI polymorphism (280) 
and IRS-1 (281). In Mexican women, GDM has been associated 
with polymorphisms of the HNF4A gene (282), the TNF-α 
gene promoter (283), the MTNR1B gene (284), the CENTD2 
gene (284), the KCNQ1 haplotype (284), and the TCF7L2 gene 
(284, 285). However, polymorphisms of the fat mass and obesity-
associated (FTO) and the TCF7L2 genes have not been associated 
with GDM in Brazilian women (286), and SLC16A11 locus was 
not associated with GDM in Mexican women (284).
Among Mexican American subjects recruited in the San 
Antonio Family Heart Study, DNA methylation levels at five CpG 
sites, mapping to three well-characterized genes (TXNIP, ABCG1, 
and SAMD12) independently explained 7.8% of the heritability 
of type 2 DM (287). In the same population, individuals with 
the hypertriglyceridemic waist phenotype [waist circumference 
≥95  cm in men and ≥80  cm in women] combined with high 
serum TG concentration (≥2.0 mmol/L in men and ≥1.5 mmol/L 
in women) were found to have epigenetic changes (DNA meth-
ylation) in genes involved in β oxidation of long-chain fatty acids 
(CPT1A) and triglyceride storage (ABCG1) (288).
In summary, these findings have shown the broad complexity 
of the pathophysiology of metabolic disease and research focused 
on Hispanics/Latinos. Broader attention to different heritages 
should be considered in future studies to better stratify subjects at 
risk for type 2 DM and develop intervention strategies according 
to different genotypic and phenotypic traits.
iNTeRveNTiONS TO PReveNT TYPe 2 
DM AMONG HiSPANiCS/LATiNOS
Lifestyle interventions to Prevent Type 2 
DM in Hispanic/Latino women with 
History of GDM
The increasing prevalence of obesity and metabolic disease in 
young Hispanics/Latinos (and other racial/ethnic groups) has 
raised thought-provoking questions about the role of maternal 
health and the intrauterine environment on the child’s future 
risk for type 2 DM and obesity. As previously described, women 
who experience GDM are at high risk of developing GDM in 
subsequent pregnancies and type 2 DM, and their children are at 
increased risk of metabolic disease.
The quality of dietary fat intake (289) and PA (290–293) 
during mid-pregnancy have been as proposed factors that could 
influence the risk of GDM in Latin American women. However, 
clinical studies evaluating the effect of exercise training on 
pregnancy outcomes have yielded inconsistent or even conflic-
tive results (292, 294). In a systematic review by Perales et  al., 
the authors concluded that the combination of aerobic and resist-
ance training during pregnancy seemed to produce the most 
favorable effect on different maternal health parameters, but that 
this combination (or either type of exercise separately) yielded 
an overall weak effect on reducing GDM (294). Previous history 
of GDM, preexisting overweight or obesity, gestational weight 
gain, intensity, frequency, duration, and timing of exercise, and 
adherence to the PA regime may be factors impacting program 
efficacy (292, 294).
Research focused on preventing GDM or type 2 DM in women 
with a history of GDM—especially Hispanics/Latinas—has 
been scarce. Some studies have evaluated PA and weight gain/
retention during pregnancy or postpartum (295–297). In the 
Behaviors Affecting Baby and You Study (n = 110 women at risk 
of GDM, 60% Hispanic/Latina) participants were randomized to 
either a 12-week tailored PA intervention or usual wellness care 
(295). Women on the tailored exercise intervention had smaller 
decrease in postpartum PA than the control group (−1.0 MET-
hours/week versus −10.0 MET-hours/week). In the Diet Exercise 
and Breastfeeding Intervention Study (n = 116, 35.5% Hispanic/
Latina), pregnant women with GDM were randomized to either 
a Diabetes Prevention Program (DPP)-modeled intervention 
that started during pregnancy and continued postpartum, or 
usual care to determine feasibility and changes in metabolic 
parameters (296). In a subsample of 72 participants, women who 
had lost > 2 kg experienced lower increases in fasting glucose, 
2h-glucose and homeostasis model assessment of insulin resist-
ance (HOMA-IR) at 12  months postpartum. Hispanic/Latino 
women were more likely to maintain or gain weight postpartum 
than women from other racial/ethnic groups (296).
In the Gestational Diabetes’ Effects on Moms Study (n = 2,280 
women with GDM, 22.2% Hispanic/Latina), a DPP-modeled 
intervention between 6  weeks and 6  months postpartum was 
compared to a usual care (mailed recommendations only) (297). 
The intervention arm had 28% higher odds of meeting postpartum 
weight goals than usual care. A greater proportion of women on 
the intervention arm had less weight retention at 6 weeks (25.5 vs. 
22.4%) and 6 months postpartum (30.6 vs. 23.9%, mean weight 
lost =  1.89 vs. 0.94 kg) compared to the women in usual care. 
However, the difference was no longer significant at 12 months 
(33.0 vs. 28.0%, mean weight lost =  1.19 vs. 0.50  kg). Also, at 
6 months postpartum, the intervention arm had a greater increase 
in vigorous-intensity PA (mean 15.4 min/week) than usual care.
In the Parish Nurse Intervention Program (298), 100 Mexican 
American women with GDM were randomized to an interview-
based intervention assessing health-promoting behaviors and 
lifestyle or to usual care. At postpartum, intervention participants 
reported higher scores on health-promoting behaviors than 
women receiving usual care. While promising, there were no 
significant differences in blood glucose, HbA1c, macrosomia, 
and other biometric parameters. In the Dulce Mothers Project, 
84 Hispanic/Latino women with previous GDM were rand-
omized to a shortened 8-week DPP-modeled intervention, 
or usual care (299). After 6  months, intervention participants 
reported a significantly higher PA and lower fat intake, but there 
were no changes in body weight or BMI. Although changes in 
HbA1c% (5.73–5.82%), total cholesterol (180–169.9  mg/dL), 
LDL-C (107.8–100.4 mg/dL), and TGs (124–110.3 mg/dL) were 
statistically significant, they were not clinically significant. In 
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the Estudio Vida (300), 68 pregnant Hispanic/Latino women 
of unspecified ancestry were randomized to a 6-month cultur-
ally and linguistically modified lifestyle intervention (monthly 
in-person behavioral counseling, and five telephone-delivered 
booster sessions, plus follow-up 6 weeks postpartum) or to usual 
care, to compare PA, gestational weight gain, infant BW, and 
biomarkers of insulin resistance postpartum. Although the inter-
vention was shown to be feasible, no changes were observed in 
any of the outcomes (300).
Some of the studies described above did not report the 
Hispanic/Latino heritage group of the participants and/or assess 
cardiometabolic markers. In addition, it is unknown whether 
the follow-up of participants continued beyond the interven-
tion period, and whether the risk for future GDM or type 2 DM 
was reduced. Other interventions focused on Hispanic/Latino 
women with history of or at risk of GDM and involving lifestyle 
intervention have been proposed (301, 302) have been proposed 
or initiated. However, results have not yet been published.
Lifestyle interventions to Prevent Type 2 
DM in Hispanic/Latino Youth in the US and 
Latin America
Little information is available of type 2 DM prevention efforts 
focusing on the youth (303). To date, no published investigations 
are available to address type 2 DM prevention in Hispanic/Latino 
youth with prediabetes. Although programs designed to prevent 
childhood and youth obesity have been extensively reviewed, 
these seldom assess blood pressure, lipids and lipoproteins and 
other metabolic markers, or adiposity (304–311). The effective-
ness trials for prevention of type 2 DM among youth are further 
challenged by a lack of consensus on parameters for disease risk 
indicators (adiposity, CV risk markers, resting energy expendi-
ture), especially during puberty, and its associated changes in 
body composition, insulin sensitivity and or insulin secretion 
(312–317).
Weight Loss and Obesity Prevention Trials
Weight loss interventions focusing on children with overweight 
or obese have resulted in improved metabolic outcomes such as 
insulin sensitivity, lipids and adiposity measures (318–324). Most 
of these trials involved medium to high-intensity interventions 
focusing on physical activity (PA) and dietary intake (309, 311, 
325). Interventions delivered in schools with home involvement 
(PA-only interventions), or with home and community compo-
nents (diet and PA interventions) have produced the strongest 
evidence of the metabolic benefits of weight loss and, consequently, 
childhood obesity prevention in the US and Latin America 
(310, 325, 326).
While promising, there are few weight gain prevention 
interventions specifically focusing on Hispanics/Latinos in the 
US and Latin America (304, 308, 327). Reviews of childhood 
obesity interventions in Latin America and the Caribbean report 
encouraging trends in childhood obesity prevention and treat-
ment programs in schools (328), healthcare (329), and settings 
such as home, summer camps and family clinics (330). However, 
these studies were mostly carried out in Mexico and Brazil, only 
three were randomized clinical trials (RCTs), and most did not 
include appropriate pediatric measures for BMI or participants’ 
ages (327). In the US, evaluations of community-based inter-
ventions targeting multiple predictors of childhood obesity are 
underway via the CDC-funded Childhood Obesity Research 
Demonstration Projects (CORD) (331–334). Two of the sites will 
focus specifically on Hispanic/Latino populations.
Dietary Considerations
Although there is no prescribed diet for diabetes prevention 
among youth, reductions of saturated fats and sugars and 
increases in fruits, vegetables, and fiber are expected to prevent 
overweight among children (335, 336) and therefore are also used 
in weight loss intervention trials. However, some argue that diets 
for type 2 DM prevention among youth should instead focus on 
low-glycemic foods (337). Small trials that test the safety and effi-
cacy of intense diet modifications suggest that low-glycemic food 
choices decrease waist circumference, BMI z-score, and insulin 
resistance—assessed through the HOMA-IR—compared to 
higher glycemic food choices (323, 325, 337–341). Some authors 
argue that these diets lead to greater decreases in adipose tissue 
compared to low-energy and low-fat diets (338, 342). In terms 
of metabolic effects of these diets specifically among Hispanics/
Latinos, evidence is still emerging (325).
Physical Activity Considerations
Intervention trials involving exercise only (without diet restric-
tions) among youth and adults have shown effects on metabolic 
outcomes and cardiorespiratory fitness without affecting weight 
or fat mass (343–349). Data specific to Hispanics/Latinos are 
limited, but in Mexico, Macías-Cervantes et al. observed a sig-
nificant decrease in insulin and HOMA-IR after a randomized 
trial of a 12-week exercise training intervention in a RCT of 76 
children, aged 6–9 years, with no significant changes in BMI or 
diet between control and intervention groups (347). Of note, the 
ADA recommends that children engage in 60 minutes of exercise 
per day most days, and that they limit time in front of a screen 
to less than 2 hours a day as a type 2 DM prevention strategy in 
children (336).
Preventing Prediabetes in School-Aged Children
DPPs in school settings have been somewhat successful at increas-
ing PA (and sometimes improving diet) via education and hands-
on activities. However, their effects on BMI, adiposity measures, 
and lipids have been inconsistent (305, 350–353). Results are 
difficult to compare due to the range of both the cardiometabolic 
risk indicators assessed and the age of the children included in 
the studies.
Lifestyle intervention trials have been conducted in schools 
with large (>50%) Hispanic/Latino populations to achieve 
change in metabolic and anthropometric outcomes among 
normal-weight students. These interventions have often involved 
PA and healthful nutrition education components and activities 
that are incorporated into the schools’ curricula (regular and PA 
classes) and cafeteria. After 4–7 month interventions involving 
elementary- and middle-school children, several studies reported 
significant improvements in behavioral or metabolic outcomes, 
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without an effect on anthropometrics (354–356). Two additional 
studies with similar school-based programs reported improve-
ments in metabolic and anthropometric parameters in the US 
and Brazil (350, 357), yet, not all studies have yielded significant 
results. For example, the HEALTHY study, a larger school RCT 
in seven centers in the US in which children in middle school 
(sixth to eighth grade, 54.2% Hispanics/Latinos) were followed, 
did not observe significant decreases in overweight/obesity, lipid, 
hypertension, or other metabolic markers among Hispanics/
Latinos (358, 359).
Studies that focus on older Hispanic/Latino youth (aged 
14–17 years) are less consistent in their findings. A small RCT 
in Brazil (360) reported that a high-intensity exercise interven-
tion for 43 adolescents with obesity did not improve BMI, waist 
circumference, blood glucose, physical fitness, HDL-C, or lipids. 
Other studies in older Hispanic/Latino teenagers (14–17 years) 
with obesity in the US or Mexico used similar dietary intake-
targeted interventions for an average 4-month period. Although 
they reported significant changes in some anthropometric meas-
ures, physical inactivity, diet, and cardiometabolic risk factors, 
they were insufficiently powered and did not include controls 
(361–363).
Lifestyle interventions to Prevent Type 2 
DM in Hispanic/Latino Adults in the US 
and Latin America
The evidence for successful type 2 DM prevention interventions 
among adults is growing. However, the increasing prevalence and 
incidence of type 2 DM among Hispanic/Latino adults suggest 
that preventive programs have not caught up with the needs of 
this population.
The DPP
The DPP is a seminal type 2 DM prevention trial (364). It 
recruited an ethnically diverse (N  =  3,234, 16% Hispanics/
Latinos) cohort and established a multisite program that dem-
onstrated that a lifestyle intervention targeting 7% body weight 
reduction and increase in PA (goal =  150  minutes per week) 
effectively reduced by 58% (compared to placebo) the incidence 
of type 2 DM among persons at high risk, and compared to 31% 
reduction with metformin (364, 365). The reduction of diabetes 
incidence was similar among race/ethnic groups, including 
Hispanics/Latinos (364). The percent of weight loss achieved 
by Hispanics/Latinos in the lifestyle intervention arm (women 
7.3%, men 7.7%) was close to that of NHWs (women 7.9%, men 
8.5%) (366).
Lifestyle Interventions Modeled after the DPP in 
Hispanics/Latinos in the US
The success of the DPP has sparked numerous attempts to modify 
this individual-based intervention for delivery in various com-
munity settings serving culturally diverse groups (367–379). 
Many of these translations appear to be effective for weight loss 
and improvement in cardiometabolic parameters (368, 379), 
although questions remain as to appropriate dosage that makes 
interventions both accessible and cost-effective, as well as the 
way in which these interventions have been culturally adapted to 
different populations.
A recent review identified only five RCTs designed to evalu-
ate lifestyle interventions aimed to reduce risk of type 2 DM in 
Hispanics/Latinos (measured by reduction of weight or HbA1c) 
(380), and only two were deemed to have a strong quality rating. 
These two studies were conducted in women only (370) or mostly 
(>70%) (368), and only one of them reported a significant reduc-
tion in HbA1c (368).
Most studies designed for type 2 DM prevention among 
Hispanics/Latinos culturally tailor their programs to the 
population of interest (367–369, 371, 381). A recent review 
of culturally tailored type 2 DM prevention interventions in 
US Hispanic/Latino adults described the varied approaches to 
cultural tailoring, which ranged from use of bilingual materials 
to community input on program content (380). As is the case 
in virtually all culturally adapted studies, none assessed the 
relative importance of various cultural adaptation elements, 
did not compare culturally adapted interventions and non-
adapted approaches (380), and did not specify participants’ 
ancestry or country of origin. While budgetary limitations 
often present barriers to these analyses, it would be important 
to ascertain the usefulness of elements of cultural adapta-
tion, as well as to determine the variability of health-related 
behaviors by cultural origin (84, 163, 382–384). There is a 
critical need for culturally adapted interventions to provide 
more detailed information on the methodology followed in the 
cultural adaptations, beyond the translation of materials, as 
well as to address the linguistic needs of many Latin American 
immigrants from indigenous communities, for whom Spanish 
is not a first language.
In Latin America, there seem to be no published studies 
modeled after the DPP, but several RCTs have evaluated the 
effect of lifestyle interventions on weight and metabolic out-
comes among adults in Mexico and Brazil (384). The RCTs 
varied in size (N =  51–241), intervention dosage (weekly to 
monthly), duration (6–12 months), and specific intervention 
components. The dietary interventions included the DASH 
diet (385), low-glycemic diets (386), or diets recommending 
olive oil, fruits, and vegetables (387). The studies reported 
significant changes in body weight loss and/or metabolic 
markers, including fasting blood glucose, HbA1c, and lipids 
(386–390).
Pharmacological interventions to Prevent 
Type 2 DM in Hispanic/Latino Adults in the 
US and Latin America
A few pharmacological interventions focused on preventing 
or delaying type 2 DM in Hispanics/Latinos have been pub-
lished (391–395). The PPAR γ agonists troglitazone (391) and 
pioglitazone (392) have demonstrated long-term preservation 
of β-cell function in Hispanic/Latino women with a history of 
GDM. Troglitazone significantly reduced the annual incidence 
rate of type 2 DM (5.4 versus 12.1% for placebo) over a median 
30-month follow-up (391), and pioglitazone demonstrated a 
significant decrease over 1-year period (392).
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Boyko et  al. reported a significant and greater reduction in 
diabetes incidence (hazard ratio  =  0.18 over approximately 
5  years, P  =  0.0242) in Latinos taking rosiglitazone, another 
PPAR γ agonist, and South Asians showing the lowest reduction 
(393). De Fronzo et al. reported a similar effect of pioglitazone at 
reducing diabetes incidence (hazard ratio = 0.28 over 2.4 years, 
P < 0.0001) among NHWs, AAs and Hispanics/Latinos compared 
to placebo (394).
O’Brien et al. (395) compared a 12-month intensive lifestyle 
intervention (DPP-modeled) led by promotoras to metformin, 
and to usual care in a group of 85 Hispanic/Latino women 
(aged ≥ 20 years) with prediabetes (IFG and/or HbA1c 5.7–6.4%). 
The investigators observed a significant reduction in weight 
(−4.0 kg or 5.0%, P < 0.001) as well as in BMI in women on the 
lifestyle intervention compared to the other groups. However, no 
significant changes in blood pressure, biochemical parameters, 
or HOMA-IR were observed. Of note, the mean adherence to 
metformin was 66.4%.
Pharmacological Interventions for Cardiometabolic 
Risk Factors in Hispanic/Latino Adults in the US and 
Latin America
Pharmacological interventions specifically designed to improve 
cardiometabolic risk factors in Hispanics/Latinos at high risk of 
type 2 DM are limited. Despite this limitation, we would like to 
highlight some key findings.
Four RCTs (396–400) designed to compare the effectiveness 
of combinations of angiotensin-converting enzyme (ACE) inhibi-
tors or angiotensin II receptor blockers (ARBs) on blood pressure 
reduction and/or prevention of CV events with other antihyper-
tensive medications reported that Hispanics/Latinos demon-
strated good response to the therapies and maintenance of blood 
pressure control, similar or even superior than that observed in 
NHWs (396–399). In one of the trials, the addition of trandolapril 
to the treatment was associated with a lower incidence of diabetes 
and CV events among Hispanics/Latinos than in non-Hispanic 
participants (398). This observation is consistent with previous 
clinical trials (in which Hispanics/Latinos had not been included) 
that reported a lower incidence of type 2 DM associated with ACE 
inhibitors and ARBs (401, 402). Also, a secondary data analysis 
on one of the trials revealed that a significantly larger percent 
(75%) of Hispanic/Latino women (n = 5,017) reached blood pres-
sure goals compared to 68% of NHW women (n = 4,710), and 
that Hispanic/Latino women experienced fewer CV events (5.7 
versus 12.3%) (403). In addition, Punzi et al. reported a significant 
reduction in blood pressure in Hispanics/Latinos with Stage I-II 
hypertension associated with nebivolol (β blocker) (404). Blood 
pressure control was achieved by 32–71% of participants depend-
ing on the dose. Some of these studies reported the Hispanic/
Latino heritage group of the participants or the Latin American 
countries where the studies were conducted. Other studies did 
not report nationalities or heritage group.
The results of the studies described above suggest Hispanics/
Latinos experienced similar or better response to antihyperten-
sive therapy than patients from other demographic groups (405). 
In contrast, Yi et al. did not observe an increased blood pressure 
control with self-blood pressure monitoring in a low-income 
urban setting (406). Thus, the good response to hypertensive 
medications observed among Hispanics/Latinos in clinical tri-
als may be both physiological and dependent on a controlled 
research setting. Future research may address underlying self-
efficacy and contextual barriers that impeded the success of the 
self-monitoring and blood pressure control outside of clinical 
trials.
Various clinical trials evaluating the efficacy of lipid-lowering 
agents have reported significant reductions of total cholesterol 
and LDL-C, or CRP in US Hispanics/Latinos or Latin Americans 
(407–410), and comparable to reductions experienced by NHWs 
(407, 408). These studies have also reported good medication 
tolerance.
Policies and Priorities and Diabetes 
Prevention Research in Latin America
Countries throughout Latin America and the Caribbean are 
starting to raise awareness about chronic disease, including type 2 
DM treatment and prevention. For example, the Latin American 
Association for Diabetes published guidelines about the treat-
ment and management of type 2 DM across medical associations 
in 17 countries (411). During the 2016 Pan American Health 
Organization (PAHO) symposium on Diabetes in the Americas, 
various countries described the epidemiology of diabetes in 
terms of incidence, prevalence, mortality, and risk factors. The 
review discussed policies or public awareness programs in place 
or designed to raise awareness of diabetes management focused 
mostly on nutrition education and physical activities (412).
Increased activities about prevention and treatment of type 2 
DM, such as those described during the PAHO Diabetes in the 
Americas symposium, can be leveraged to increase our under-
standing of whether strategies designed to target type 2 DM risk 
factors (i.e., prediabetes, hypertension, and obesity) can actually 
lead to lower disease risk. As of May 2015, Chile and Mexico had 
implemented national-level taxes on sodas, and evaluations for 
these programs are underway (413). Various Latin American 
countries have set strategies, which have not yet been evaluated, 
to increase awareness about the harmful effects of transfatty acids 
(414) and of high salt intake (415–419). Other population-level 
initiatives include the creation of guidelines for healthful eating 
and PA; the creation of Ciclovía-Recreovía in Colombia (420), 
additional training of health care professionals to improve dia-
betes care, and diabetes screening initiatives in Chile, Argentina, 
and Honduras, nutrition labeling in Ecuador, and the ban of 
unhealthful foods in schools in Costa Rica, Perú and Guatemala 
(418). These new strategies present a unique opportunity to 
evaluate the process of implementation, the role of stakeholders 
in their design and implementation, and their eventual impact 
on anthropometric, lipids, and metabolic indicators or diabetes 
prevalence and treatment.
PReveNTiNG TYPe 2 DM iN HiSPANiCS/
LATiNOS—A HOLiSTiC FRAMewORK
The epidemiology, etiology, and interventions studies selected 
for this review provide important insights on the magnitude 
FiGURe 2 | Framework of opportunities to enhance research and clinical care oriented toward preventing type 2 diabetes in Hispanics/Latinos in the US and Latin 
America.
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of the prevalence, the complexity of potential mechanisms of 
disease, and the approaches toward preventing type 2 DM in 
Hispanics/Latinos. Based on these insights, it is evident that the 
successful prevention of type 2 DM in Hispanic/Latino popula-
tions in the US and Latin America would need a fundamentally 
radical transformation. In the era of personalized medicine, this 
transformation would require a holistic mission and a multidis-
ciplinary approach.
This holistic framework integrates key domains that inter-
act with each other (Figure 2). Within each domain we have 
identified areas that represent opportunities for enhancing 
the prevention of type 2 DM in Hispanic/Latino popula-
tions—whether as a part of a research program or clinical 
care intervention. The Hispanic/Latino individual is at the 
center, and representing the most important element of the 
framework.
Our understanding of the burden of diabetes (type 1 and 
type 2) in Hispanic/Latino populations remains insufficient 
and should be prioritized. The development of effective type 2 
DM preventive efforts requires continued surveillance of the 
burden of disease and its risk factors using disaggregated data on 
Hispanic/Latino subgroups. Adequate representation of diverse 
populations would enhance the identification of different phe-
notypes, and potential disease mediators and interactions. More 
detailed epidemiologic data at the country level in Latin America 
are urgently needed.
Consistency and standardization of methodology to assess 
the prevalence of diabetes in Hispanic/Latino populations would 
more accurately estimate its prevalence within and among coun-
tries and ethnic/heritage groups, and enhance comparison across 
studies. The need for consistency of methodology and for detailed 
disaggregated data could be addressed through the creation of 
repositories of deidentified data, and consortia (including repre-
sentatives from research study groups, academic centers, medical 
societies, health authorities, and others) that would strategize the 
harmonization and/or standardization of methodology for data 
collection and analysis.
The identification of Hispanics/Latinos and Latin Americans 
in health-related research is inconsistent. Although the concept 
of a Hispanic/Latino monolith is slowly changing, the continued 
use of umbrella terms like “Hispanic” or “Latino” limits the ability 
of public health and clinical researchers to evaluate and address 
type 2 DM risk factors that may impact or manifest differently 
across Hispanic/Latino heritage groups; and this in turns delays 
the development of effective preventive strategies.
The etiology of type 2 DM is complex, and the research stud-
ies discussed in this review demonstrated areas in which further 
research could be developed. In this regard, it is not completely 
understood whether the oxidative stress, inflammatory and 
endothelial changes described in placental and umbilical cord 
tissue of pregnancies in which the mother had obesity or GDM 
could be prevented or reverted during pregnancy, and the impact 
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that such reduction would have on the child. At the same time, 
although GDM has been associated with increased risk for mater-
nal type 2 DM, it is not clear whether GDM increases the mother’s 
risk for CVD. Determining GDM risk (i.e., a predictive profile) 
for Hispanic/Latino women might identify those at risk early in 
pregnancy or before conception, so preventive interventions are 
tailored and initiated earlier.
Although obesity is associated with increased risk for type 
2 DM, the distribution of adipose tissue (i.e., steatosis) has 
been associated to specific metabolic (421, 422) and cardiac 
structural abnormalities (423, 424). The study of other type 2 
DM risk factors previously mentioned (e.g., sleep-disordered 
breathing, gut microbiome, environmental exposures) could 
uncover new mechanisms of disease, which can be turned into 
additional opportunities for interventions in Hispanic/Latino 
populations.
As the field of genetics/epigenetics/genomics continues evolv-
ing, additional insights on the gene-environment interaction 
(e.g., chronic stress, environmental endocrine disruptors, other 
environmental exposures) and the differences in susceptibility 
to type 2 DM experienced by different Hispanic/Latino heritage 
groups in the US and Latin America might be uncovered. Thus, 
the inclusion of Hispanics/Latinos in these research studies needs 
to improve.
The clinical assessment of Hispanics/Latinos at risk of 
devel oping type 2 DM needs to be comprehensive. The medical 
history needs to account underlying medical, nutritional, physi-
cal fitness, emotional, behavioral, cultural, and social factors. 
A detailed family history will uncover heredity patterns that could 
be relevant in the decision-making regarding therapy or genetic 
testing. The individuals’ family dynamics and social network 
may also uncover dietary habits and values (425–427) that could 
impact the disease risk, the need for pharmacological therapy, 
and the effectiveness of the intervention. Socioeconomic fac-
tors will influence both type 2 DM risk and the success of any 
prevention strategy (368–371, 427–431). Access, availability and 
quality of food; social and family responsibilities, social network 
and support; stressors; of the built environment, neighborhood 
safety, transportation, and access to recreational activities; 
availability and access to health services, health insurance 
type, and coverage; access to and utilization of medications and 
medical services; formal education attained and health literacy; 
and occupation(s), work shift, and occupational safety are some 
of the factors that will influence the success of the interven-
tion. Incorporating these factors into the clinical assessment 
could uncover obstacles requiring alternative or additional 
interventions.
As previously discussed, Hispanics/Latinos at risk of type 2 
DM often also have other cardiometabolic factors that increase 
the risk for developing type 2 DM or CVD (95, 146, 148, 
432, 433). While lifestyle intervention would ideally be recom-
mended to every patient at risk, some patients would also need 
pharmacological therapy to control other cardiometabolic fac-
tors (66, 434). Prevention of use of tobacco or its cessation should 
also be addressed, when applicable.
The difference in prevalence of diabetes across Hispanic/
Latino heritage groups presents an opportunity to study 
potential genetic, biological and environmental interactions 
that lead to different manifestations of the disease. Deep meta-
bolic phenotyping, (i.e., assessment of glucose homeostasis, 
insulin sensitivity, insulin secretion, α-cell and β-cell function, 
adipose tissue distribution) along with a comprehensive clini-
cal assessment (including age, sex, clinical presentation of the 
disease, detailed medical history, etc.) may uncover important 
differences or similarities in type 2 DM phenotypes among 
Hispanic/Latino heritage groups, and biological or health 
determinants that could influence type 2 DM risk. Given the 
diversity of the Hispanic/Latino population, the feasibility of 
such enterprise could be addressed through collaborations like 
those mentioned above, exploring the use of clinical databases, 
and creating patient/data registries, among other potential col-
lective efforts.
Type 2 diabetes mellitus preventive strategies have mostly 
focused on weight reduction, and have produced promising 
results. However, given the increasing prevalence of obesity in 
the Hispanic/Latino populations, type 2 DM diabetes and obesity 
preventive efforts may require even more intensive approaches, 
perhaps through risk stratification. Preventive efforts focusing 
on those at higher risk due to age, health status, medications, 
sedentary lifestyle, family history of type 2 DM or GDM might 
be different than the strategies for those who have lower sus-
ceptibility. The timing of prevention should also be considered. 
Earlier onset of obesity has been associated with higher risk 
of developing type 2 DM (173–175), for example. Also, risk 
stratification should be carefully determined and considering 
all factors mentioned above. For instance, the DPP reported 
that over a 10-year follow-up period from randomization, the 
initial differences in incident diabetes among treatment arms, 
including the lifestyle intervention, began to narrow (435). 
Through a retrospective analysis, the investigators examined 
participants’ susceptibility to type 2 DM, including genetic 
risk scores (GRSs) (435, 436). The investigators concluded that 
although clinical and genetic susceptibility could influence 
risk to develop type 2 DM, GRS alone did not determine the 
success of the lifestyle intervention; at the highest quartile of 
GRS, intensive lifestyle intervention was effective at reducing 
risk (435, 436).
Few behaviors are as closely tied to culture as diet and self-
care. What, when, and how much we eat, as well as our notions 
of health and disease, including whose advice we seek, are 
firmly grounded in the cultural context which shapes us. It may 
influence beliefs about what causes diabetes, whether to engage 
in type 2 DM risk-reduction activities, seek advice regarding 
the disease, and decide which treatment options are followed. 
Despite their impact on health and disease management, cultural 
considerations are often an afterthought in the development 
and implementation of preventive or treatment interventions 
targeting type 2 DM in Hispanic/Latino populations. A recent 
review found only 12 published studies on behavioral interven-
tions aimed at reduction of type 2 DM and specifically designed 
for Hispanic/Latino adults (380). All interventions were offered 
in Spanish and took place in community settings, and nine 
included materials for individuals of low literacy. However, only 
two included Hispanic/Latino foods or recipes, community 
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input in the intervention content, and addressed cultural beliefs 
regarding diabetes. Thus, it appears that for most studies, the 
process of infusing culture into interventions remains at the 
surface structures (language and setting in which intervention 
is delivered), without fully incorporating cultural values and ele-
ments into intervention messages, materials, design, and imple-
mentation (437). Given the evidence that culturally coherent 
behavioral interventions for diabetes prevention/management 
among Hispanic/Latino groups are more effective than usual 
care in improving HbA1c, weight/body mass index, lipid, blood 
pressure, dietary intake, PA, and diabetes knowledge (438), there 
is a strong case for ensuring the presence of cultural-competency 
components in every diabetes-related healthcare service inter-
vention. Cultural competence must be at the core of clinical 
care and the design and implementation of research studies and 
large-scale interventions.
Lifestyle intervention studies to prevent type 2 DM in 
Hispanics/Latinos have mostly been focused on short-term goals 
of weight reduction, and increasing PA. While they have demon-
strated modest success at meeting these goals, follow-up periods 
have been insufficiently long to demonstrate prevention or delay 
of type 2 DM. Initiating lifestyle interventions before pregnancy 
(to prevent GDM, for example), and improving representation 
of women of various Hispanic/Latino heritage groups, should be 
seriously considered. Studies focused on children and adolescents 
could explore the impact of factors, such as maternal health, 
prenatal care, and child’s development on preventive interven-
tions. Advances in the field will require funding opportunities 
that allow for longer follow-up periods, permit the examination 
of interventions and outcomes for different Hispanic/Latino 
populations, and allow for comparisons of various elements 
of cultural adaptation. On the other hand, integrating research 
interventions within established clinical settings or health systems 
could be resource-efficient way to implement research studies on 
type 2 DM prevention, including the follow-up of research study 
participants.
Quality of life and savings in disability-adjusted life years 
resulting from delaying the onset of type 2 DM should be 
quantified and qualified, especially among high-risk populations 
like Hispanics/Latinos. Also, the evaluation of type 2 DM risk 
prevention in multilevel community studies to prevent child-
hood obesity (331, 332), coupled with mass media campaigns to 
increase awareness of type 2 DM prevention (336, 439), and other 
risk factors for diabetes, is warranted.
The success of large culturally tailored interventions, such 
as those modeled after the DPP, underscore the promise that 
such interventions might result in improved quality of life, 
higher productivity, and reduced morbidity and mortality for 
Hispanic/Latino populations. However, it is critical to remain 
aware that the vast heterogeneity in the Hispanic/Latino popula-
tion requires clinicians and researchers alike to avoid relying on 
vague and largely unexamined concepts, such as familism and 
marianism without first verifying their relevance in the popula-
tion of interest. Often, the uncritical acceptance of these values as 
omnipresent in individuals of Hispanic/Latino origin results in 
the automatic assumptions that, for example, interventions must 
be family based. Upon closer examination, studies have found 
that the Hispanic family unit is much more complex, and less 
unconditionally supportive, than it is often assumed to be, and in 
many cases, some Hispanic/Latino women prefer women-only 
group interventions without the inhibiting presence of family 
members, children, or spouses (440, 441).
In both clinical and research programs, engagement of stake-
holders, not only including the patient population and the 
healthcare provider team, but also administrative clinic and 
research staff, is critical for the success of health-promotion 
interventions. A bidirectional communication style, from clini-
cians/investigators to patients and community, is necessary to 
ensure the cultural coherence, accessibility, and sustainability of 
a program. Individuals who are thoroughly competent in the cul-
tural, socioeconomic, and even geographic context of the target 
population can navigate cultural nuances of these heterogeneous 
populations and provide invaluable guidance in the design and 
implementation of both large- and small-scale preventive and 
treatment efforts.
Upon designing a research project or implementing a clinical 
program to prevent type 2 DM in Hispanics/Latinos in the US 
and in Latin America, other challenges need to be acknowledged. 
Insufficient institutional (government, academic, etc.) interest 
or commitment, lack of public awareness on the importance 
of prevention, insufficient financial and human resources, and 
political issues are some of the challenges faced across the conti-
nent (442–444). Whereas out of the scope of this review, proposed 
models of an international collaborative initiative (442) and of an 
implementation cycle and a translatability scale for identifying and 
implementing effective solutions to address the rising burden of 
chronic diseases in low-middle income countries, specifically CVD 
(444), might set the stage for future type 2 DM prevention initiatives 
in the continent.
The progressive and sustained increase in type 2 DM among 
Hispanics/Latinos is a clear indicator that preventive efforts need 
to be seriously and urgently reframed. This will require a better 
understanding of the extent and etiology of the disease, creating 
solutions through multidisciplinary approaches, and a funda-
mentally radical transformation in our priorities as individuals 
and as communities.
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